US20220213208A1 - Anti-bcma antibodies - Google Patents
Anti-bcma antibodies Download PDFInfo
- Publication number
- US20220213208A1 US20220213208A1 US17/444,107 US202117444107A US2022213208A1 US 20220213208 A1 US20220213208 A1 US 20220213208A1 US 202117444107 A US202117444107 A US 202117444107A US 2022213208 A1 US2022213208 A1 US 2022213208A1
- Authority
- US
- United States
- Prior art keywords
- seq
- variable domain
- antibody
- cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 210000003719 b-lymphocyte Anatomy 0.000 claims abstract description 97
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 claims abstract description 68
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 claims abstract description 68
- 238000000034 method Methods 0.000 claims abstract description 63
- 210000004180 plasmocyte Anatomy 0.000 claims abstract description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 22
- 208000035475 disorder Diseases 0.000 claims abstract description 19
- 206010025323 Lymphomas Diseases 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 101
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 claims description 60
- 230000027455 binding Effects 0.000 claims description 23
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 17
- 108091007433 antigens Proteins 0.000 claims description 17
- 102000036639 antigens Human genes 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 8
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 8
- 208000007452 Plasmacytoma Diseases 0.000 claims description 8
- 206010002412 Angiocentric lymphomas Diseases 0.000 claims description 6
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims description 6
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 6
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 6
- 230000036210 malignancy Effects 0.000 claims description 6
- 230000003211 malignant effect Effects 0.000 claims description 6
- 208000034578 Multiple myelomas Diseases 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims description 4
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims description 4
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims description 4
- 230000004957 immunoregulator effect Effects 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 206010001935 American trypanosomiasis Diseases 0.000 claims description 3
- 208000002267 Anti-neutrophil cytoplasmic antibody-associated vasculitis Diseases 0.000 claims description 3
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 claims description 3
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 3
- 208000024699 Chagas disease Diseases 0.000 claims description 3
- 208000024869 Goodpasture syndrome Diseases 0.000 claims description 3
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims description 3
- 208000003807 Graves Disease Diseases 0.000 claims description 3
- 208000015023 Graves' disease Diseases 0.000 claims description 3
- 206010053574 Immunoblastic lymphoma Diseases 0.000 claims description 3
- 208000011200 Kawasaki disease Diseases 0.000 claims description 3
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 3
- 201000003791 MALT lymphoma Diseases 0.000 claims description 3
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 3
- 206010029461 Nodal marginal zone B-cell lymphomas Diseases 0.000 claims description 3
- 201000011152 Pemphigus Diseases 0.000 claims description 3
- 206010039710 Scleroderma Diseases 0.000 claims description 3
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 3
- 206010002022 amyloidosis Diseases 0.000 claims description 3
- 201000003444 follicular lymphoma Diseases 0.000 claims description 3
- 208000025750 heavy chain disease Diseases 0.000 claims description 3
- 208000006116 lymphomatoid granulomatosis Diseases 0.000 claims description 3
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims description 3
- 208000021937 marginal zone lymphoma Diseases 0.000 claims description 3
- 201000005328 monoclonal gammopathy of uncertain significance Diseases 0.000 claims description 3
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 claims description 3
- 201000006292 polyarteritis nodosa Diseases 0.000 claims description 3
- 208000017805 post-transplant lymphoproliferative disease Diseases 0.000 claims description 3
- 201000006037 primary mediastinal B-cell lymphoma Diseases 0.000 claims description 3
- 230000002685 pulmonary effect Effects 0.000 claims description 3
- 201000008158 rapidly progressive glomerulonephritis Diseases 0.000 claims description 3
- 201000006845 reticulosarcoma Diseases 0.000 claims description 3
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 3
- 208000010190 Monoclonal Gammopathy of Undetermined Significance Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 210000001806 memory b lymphocyte Anatomy 0.000 abstract description 31
- 230000000779 depleting effect Effects 0.000 abstract description 7
- 208000023275 Autoimmune disease Diseases 0.000 abstract description 6
- 150000001413 amino acids Chemical class 0.000 description 62
- 241000282414 Homo sapiens Species 0.000 description 60
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 36
- 108090000623 proteins and genes Proteins 0.000 description 35
- 102000004169 proteins and genes Human genes 0.000 description 34
- 241000699670 Mus sp. Species 0.000 description 32
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 22
- 210000002966 serum Anatomy 0.000 description 21
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 14
- 239000008280 blood Substances 0.000 description 14
- 239000000203 mixture Substances 0.000 description 14
- 241001529936 Murinae Species 0.000 description 13
- 210000000649 b-lymphocyte subset Anatomy 0.000 description 13
- 238000006467 substitution reaction Methods 0.000 description 12
- 229960002685 biotin Drugs 0.000 description 11
- 235000020958 biotin Nutrition 0.000 description 11
- 239000011616 biotin Substances 0.000 description 11
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 11
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 10
- 238000000684 flow cytometry Methods 0.000 description 10
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 9
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000001404 mediated effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108060003951 Immunoglobulin Proteins 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 102000018358 immunoglobulin Human genes 0.000 description 8
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 8
- 230000003393 splenic effect Effects 0.000 description 8
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 7
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 7
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 7
- 239000008194 pharmaceutical composition Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000003937 drug carrier Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 230000009257 reactivity Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 102100027207 CD27 antigen Human genes 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 101100383038 Homo sapiens CD19 gene Proteins 0.000 description 5
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 5
- 101000801255 Homo sapiens Tumor necrosis factor receptor superfamily member 17 Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 210000001960 double negative memory b cell Anatomy 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 210000005260 human cell Anatomy 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- 210000004988 splenocyte Anatomy 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 210000003485 unswitched memory b cell Anatomy 0.000 description 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 3
- 102100031585 ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Human genes 0.000 description 3
- 208000003950 B-cell lymphoma Diseases 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101000777636 Homo sapiens ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 Proteins 0.000 description 3
- 101000595198 Homo sapiens Podocalyxin Proteins 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000002612 dispersion medium Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000011577 humanized mouse model Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000003068 molecular probe Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000009871 nonspecific binding Effects 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 239000002777 nucleoside Substances 0.000 description 3
- 125000003835 nucleoside group Chemical group 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 101710160107 Outer membrane protein A Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 108010022394 Threonine synthase Proteins 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 102100033726 Tumor necrosis factor receptor superfamily member 17 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 239000013043 chemical agent Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- -1 coatings Substances 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 102000004419 dihydrofolate reductase Human genes 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000012997 ficoll-paque Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 102000046935 human TNFRSF17 Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000007951 isotonicity adjuster Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- XXUZFRDUEGQHOV-UHFFFAOYSA-J strontium ranelate Chemical compound [Sr+2].[Sr+2].[O-]C(=O)CN(CC([O-])=O)C=1SC(C([O-])=O)=C(CC([O-])=O)C=1C#N XXUZFRDUEGQHOV-UHFFFAOYSA-J 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 1
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 208000021161 Plasma cell disease Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 239000012505 Superdex™ Substances 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 238000011965 cell line development Methods 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 210000004700 fetal blood Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000005210 lymphoid organ Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000002687 nonaqueous vehicle Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 210000004976 peripheral blood cell Anatomy 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000003720 plasmablast Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000008389 polyethoxylated castor oil Substances 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000013587 production medium Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
Definitions
- This invention relates to antibodies that bind to the B cell surface antigen BCMA.
- the invention also relates to the use of these antibodies to detect, deplete, and otherwise manipulate various B cell subtypes.
- B cells are lymphocytes that play major roles in adaptive humoral immunity and production of antibodies that specifically recognize antigens.
- Three subclasses of B cells are na ⁇ ve B cells, memory B cells, and plasma cells.
- a B cell is said to be specific for an antigen that binds the antibodies made by that B cell.
- B cells in general are stimulated by exposure to their specific antigen (Ag).
- Na ⁇ ve B cells have not yet been exposed to their specific antigen. Such exposure (e.g., during an infection) results in proliferation of B cells and generation of sister clones.
- Sister clones can develop into plasma cells, which produce high amounts of antibody. Plasma cells may either be short lived, or may migrate into bone marrow, where they can persist for an extended period of time.
- a sister clone of an Ag-exposed B cell may also develop into a memory B cell that is quiescent until reexposed to the specific antigen.
- Memory B cells respond rapidly to reexposure to antigen by dividing to produce both plasma cells and additional memory B cells.
- Memory B cells include switched memory B cells (CD19 + CD27 high CD38 low IgD ⁇ ), unswitched memory B cells (CD19+CD27 high CD38 low IgD + ), and double negative memory B cells (CD19+CD27 ⁇ CD38 low IgD ⁇ ).
- B cells Malignant transformation of B cells leads to cancers, including some lymphomas such as, for example, multiple myeloma and Hodgkins' Lymphoma. Some autoimmune diseases, including systemic lupus erythematosus (SLE), also involve B cells. Both cancer and autoimmune diseases that involve B cells may be considered gain of function conditions, in that the B cells overgrow and/or attack parts of the body inappropriately. A possible strategy to control such diseases is to use antibodies that target the pathological B cells.
- SLE systemic lupus erythematosus
- BCMA The B cell maturation antigen
- TNFRSF17 and CD269 The B cell maturation antigen
- BCMA is a protein that has been shown to be expressed on the surface of plasmablasts (i.e., plasma cell precursors) and plasma cells, and is believed to stimulate survival. It therefore represents a potential target for B cell-related diseases.
- BCMA is a member of the TNF receptor family and binds the TNF family ligands BAFF and APRIL (reviewed in Kalled et al. (2005), Curr Dir Autoimmun 8:206-242).
- BCMA is a type III membrane protein, as it lacks the signal peptide associated with type I membrane proteins found in most TNF receptor family members.
- BCMA RNA has been detected in the spleen, lymph nodes, thymus, adrenals and liver, and analysis of a number of B cell lines indicated that BCMA mRNA levels increased upon maturation.
- Human BCMA protein has been detected on various subtypes of CD38 + B cells, particularly plasma cells (Zhang et al. (2005), Int Immunol 17:779-788; Darce et al. (2007), J Immunol 179:7276-7286; Sims et al. (2005), Blood 105:4390-4398; Avery et al. (2003), J Clin Invest 112:286-297).
- the expression of BCMA on the surface of some B cells provides a marker by which those cells may be specifically targeted.
- agents that specifically bind to BCMA and for a determination of which B cell subsets are bound by those BCMA-specific agents.
- the invention provides antibodies that specifically bind to BCMA.
- the antibodies of the invention may be used to target one or more of the following B cell subsets: plasma cells, memory B cells, and na ⁇ ve B cells.
- FIGS. 1A-1C depict_binding of anti-human BCMA mAbs on BCMA-transfected CHO cells. Binding of biotin-conjugated anti-human BCMA mAbs, visualized with Streptavidin-PE, was measured by flow cytometry on a BCMA-CHO stable cell line ( FIG. 1A ) and control, non-transfected CHO cells ( FIG. 1B ). The shaded area represents staining of cells with an isotype control mAb.
- FIGS. 2A-2F depict anti-BCMA binding to B cell subsets.
- B cell subsets in human peripheral blood were assessed by flow cytometry for reactivity to anti-BCMA mAbs. Visualization was as in FIG. 1 . The shaded area represents staining with an isotype control Ab.
- B cell subsets were plasma cells (CD19 + CD27 high CD38 high IgD ⁇ ) ( FIG. 2A ), switched memory B cells (CD19 + CD27 high CD38 low IgD ⁇ ) ( FIG. 2B ), unswitched memory B cells (CD19 + CD27 high CD38 low IgD + ) ( FIG. 2C ), double negative memory B cells (CD19 + CD27 ⁇ CD38 low IgD ⁇ ) ( FIG. 2D ), and na ⁇ ve B cells (CD19 + CD27 ⁇ IgD + ) ( FIG. 2E ).
- FIGS. 3A-3D depict anti-BCMA binding to B cell subsets isolated from healthy and SLE-afflicted individuals.
- B cell subsets in human peripheral blood from a healthy volunteer and an SLE patient were assessed by flow cytometry for reactivity to the anti-BCMA mAbs C12A3.2 and A7D12.2.
- B cell subsets were as in FIG. 2 .
- Visualization was as in FIG. 1 .
- FIG. 4 depicts flow cytometric staining of human plasma cells within the human CD45 + splenocyte compartment isolated from HSC/NSG mice. Splenic plasma cells were stained with anti-BCMA antibodies A7D12.2 (left panel; bold line) and C12A3.2 (right panel; bold line) or an isoytpe control mouse IgG2b or IgG1 Ab, respectively (thin line in both panels).
- FIG. 6 depicts flow cytometric staining for plasma cells (PCs) within the human CD45 + splenocyte compartment isolated from HSC/NSG mice treated with anti-BCMA antibody (chC11D5.1 or chA7D12.2) or human IgG1 control. Mice were injected i.p. with anti-BCMA Ab or HIgG1 control twice weekly for 2 weeks.
- PCs plasma cells
- the invention provides antibodies that bind to BCMA and certain epitopes thereof.
- the antibodies of the invention bind to one or more subsets of B cells, such as plasma cells, memory B cells, and na ⁇ ve B cells.
- the invention also provides methods of depleting B cells or subclasses of B cells, including plasma cells, memory B cells, and na ⁇ ve B cells.
- the invention provides an isolated antibody that binds to SEQ ID NO:9 and binds to plasma cells.
- the invention provides an isolated antibody that binds to SEQ ID NO:9 and binds to memory B cells.
- the invention provides an isolated antibody that binds to SEQ ID NO:9 and binds to na ⁇ ve B cells.
- Certain anti-BCMA mAbs including clone C4E2.2 (hamster IgG) generated at Legacy Biogen (6); clone VICKY-1 (rat IgG1) (Alexis Biochemicals, Lausen, Switzerland, also sold as 6D10 by Santa Cruz Biotechnology, Santa Cruz, Calif.); and clone 335004 (rat IgG2a) (R&D Systems, Inc., Minneapolis, Minn.), are outside the scope of this invention.
- the invention provides antibodies that bind specifically to SEQ ID NO:9.
- the invention also provides to antibodies that bind to the surface of B cells or subclasses thereof, including plasma cells, memory B cells (including switched, unswitched, and double negative), and/or na ⁇ ve B cells.
- the term “antibody” as used herein, includes both full-length immunoglobulins and antibody fragments that bind to the same antigens.
- the antibodies can be, e.g., a monoclonal, polyclonal, chimeric, humanized, or single chain antibody.
- the antibody fragments are Fab fragments or F(ab′)2 fragments and retain the ability to specifically bind the protein of SEQ ID NO: 9.
- the invention provides the antibodies A7D12.2, C11D5.3, C12A3.2, and C13F12.1. Each of these is a murine monoclonal antibody.
- A7D12.2 has a murine “miscellaneous” subgroup heavy chain, a heavy chain variable domain sequence that is SEQ ID NO:1, a subgroup I kappa light chain, and a light chain variable domain sequence that is SEQ ID NO:2.
- C11D5.3 has a subgroup II (A) heavy chain, a heavy chain variable domain sequence that is SEQ ID NO:3, a murine subgroup III kappa light chain, and a light chain variable domain sequence that is selected from SEQ ID NO:4, SEQ ID NO:11, and SEQ ID NO:12.
- the light chain variable domain sequence of C11D5.3 is SEQ ID NO:12.
- C12A3.2 has a subgroup II (A) heavy chain, a heavy chain variable domain sequence that is SEQ ID NO:5, a murine subgroup III kappa light chain, and a light chain variable domain sequence that is SEQ ID NO:6.
- C13F12.1 has a subgroup II (A) heavy chain, a heavy chain variable domain sequence that is SEQ ID NO:7, a murine subgroup III kappa light chain, and a light chain variable domain sequence that is SEQ ID NO:8.
- Techniques for producing single-chain antibodies specific to the protein of SEQ ID NO: 9 can be adapted from e.g., those described in U.S. Pat. No. 4,946,778.
- methods can be adapted for the construction of Fab expression libraries (see e.g., Huse et al. (1989) Science 246:1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a BCMA protein or derivatives, fragments, analogs or homologs thereof.
- Numerous techniques for humanizing non-human antibodies are well known in the art. See e.g., U.S. Pat. Nos. 5,225,539, 6,632,927, or 5,648,237, all of which are incorporated by reference.
- Antibody fragments that contain the idiotypes to a BCMA protein may be produced by any of a variety of techniques, including, but not limited to: (i) an F(ab′)2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab′)2 fragment; (iii) a Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments.
- recombinant anti-BCMA antibodies such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention.
- Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques such as, for example, the methods described in U.S. Pat. No. 7,112,421; Better et al. (1988) Science 240:1041-1043; or Liu et ai. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443.
- a chimeric form of A7D12.2 comprises a heavy chain comprising SEQ ID NO:13 and a light chain comprising SEQ ID NO:14.
- a chimeric form of C11D5.3 comprises a heavy chain comprising SEQ ID NO:15 and a light chain comprising a sequence selected from SEQ ID NO:16 and SEQ ID NO:17, preferably SEQ ID NO:17.
- a chimeric form of C12A3.2 comprises a heavy chain comprising SEQ ID NO:18 and a light chain comprising SEQ ID NO:19.
- a chimeric form of C13F12.1 comprises a heavy chain comprising SEQ ID NO:20 and a light chain comprising SEQ ID NO:21.
- a humanized form of C11D5.3 comprises a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 22-24 and a heavy chain variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 25-29.
- a humanized form of C12A3.2 comprises a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 30-33 and a heavy chain variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 34-38.
- the antibodies of the invention may comprise the heavy chain variable domain sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.
- the heavy chain variable domain sequences may consist essentially of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.
- the antibodies of the invention may comprise the light chain variable domain sequences of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12.
- the light chain variable domain sequences may consist essentially of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12.
- the invention also provides a variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to a sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7.
- the invention also provides a variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to a sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, and SEQ ID NO:12.
- the invention also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:1 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:2.
- the invention includes antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:3 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO: 4, SEQ ID NO:11, or SEQ ID NO:12.
- the invention includes antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:5 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:6.
- the invention includes antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:7 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:8.
- the invention also provides antibodies with particular complementarity determining regions (CDR).
- CDR complementarity determining regions Table 2 defines the amino acid coordinates of CDR1, CDR2, and CDR3 of SEQ ID NOs:1 through 8, 11, and 12.
- CDRs are designated using the Kabat definitions (Johnson and Wu (2000), Nucleic Acids Res 28:214-218). As used herein, the “corresponding CDR” means the CDR in the most similar position within the variable domain amino acid sequence.
- the heavy chain variable domain of antibodies of the invention may comprise CDRs such that one, two, or three of the CDRs are identical to the corresponding CDRs of SEQ ID NO:1; identical to the corresponding CDRs of SEQ ID NO:3; identical to the corresponding CDRs of SEQ ID NO:5; or identical to the corresponding CDRs of SEQ ID NO:7.
- the light chain variable domain of antibodies of the invention may comprise CDRs such that one, two, or three of the CDRs are identical to the corresponding CDRs of SEQ ID NO:2; identical to the corresponding CDRs of SEQ ID NO:4; identical to the corresponding CDRs of SEQ ID NO:6; identical to the corresponding CDRs of SEQ ID NO:8; identical to the corresponding CDRs of SEQ ID NO:11; or identical to the corresponding CDRs of SEQ ID NO:12.
- the heavy chain variable domain may comprise CDRs identical to each of the corresponding CDRs of one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7 except that one or more amino acid substitutions have been made in said CDR regions.
- CDRs of the heavy chain variable domain may have up to a total of 12 amino acid substitutions relative to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.
- the heavy chain variable domain CDRs of the antibodies of the invention may have up to 10, up to 8, up to 5, or up to 3 substitutions relative to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.
- CDR2 of SEQ ID NO:7 is replaced by CDR2 (i.e., amino acids 50-66) of SEQ ID NO:46.
- the heavy chain variable domain of an antibody of the invention may comprise CDR1 and CDR3 of SEQ ID NO:7 and CDR2 of SEQ ID NO:46.
- the heavy chain variable domain of an antibody of the invention may also comprise CDR1, CDR2, and CDR3 regions that are together at least 80%, at least 85%, at least 90%, or at least 95% identical to CDR1 and CDR3 of SEQ ID NO:7 and CDR2 of SEQ ID NO:46.
- the light chain variable domain may comprise CDRs identical to the corresponding CDRs of one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12, except for one or more amino acid substitutions in said CDR regions.
- the antibodies of the invention comprise CDRs that are identical to the corresponding CDRs of one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12, except for up to 12, up to 10, up to 8, up to 5, or up to 3 amino acid substitutions in said CDR regions.
- the light chain variable domain CDRs of the antibodies of the invention are at least 80%, at least 85%, at least 90%, or at least 95% identical to the light chain variable domain CDRs of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12.
- the substitutions in the CDR regions are conservative substitutions.
- the invention also provides antibodies that bind particular epitopes. Whether a pair of antibodies binds the same epitope is determined based on cross-blocking experiments, as described in Example 4. Cross-blocking profiles are defined for seven antibodies in Table 3. For the purposes of this disclosure, two antibodies are considered to bind to the same epitope if each one reduces the other's binding to BCMA (i.e., they mutually cross-block) by at least 90% according to the procedure described in Example 4. Similarly, antibodies that do not reduce each other's binding by at least 90% as described in Example 4 are considered to bind to distinct epitopes.
- the cross-blocking profiles of antibodies with certain variable domains are listed in Table 3. Pairs of antibodies that bind to distinct epitopes (as defined above) are noted with a “d.”
- the invention further encompasses antibodies that bind to the same epitope as antibodies A7D12.2, C11D5.3, C12A3.2, or C13F12.1.
- the invention also provides antibodies that have cross-blocking profiles that match the profiles of A7D12.2, C11D5.3, C12A3.2, or C13F12.1.
- an antibody that has the same profile as C11D5.3 binds to the same epitope as compared to C12A3.2 and C13F12.1 but binds to a distinct epitope as compared to A7D12.2, 335004, C4E2, and Vicky-1.
- the antibodies of the invention mutually cross-block one or more of A7D12.2, C11D5.3, C12A3.2, or C13F12.1 from binding the protein of SEQ ID NO: 9 by at least 80%, 85%, 90%, or 95%.
- the extent of cross-blocking is measured according to the procedure described in Example 4.
- the antibodies and antibody fragments of the invention bind to the extracellular domain of BCMA.
- the antibodies bind to amino acids 1-52, 1-51, 1-41, or 8-41 of SEQ ID NO:9.
- the invention also provides anti-BCMA antibodies that bind to one or more particular types of cell.
- the antibodies or antibody fragments of the invention may bind one or more of the following: plasma cells, memory B cells, na ⁇ ve B cells, or cells that express BCMA (SEQ ID NO:9), a protein similar thereto, the extracellular domain thereof, or a polypeptide similar to the extracellular domain thereof.
- the invention provides methods of depleting various types of cells.
- the methods comprise administering the antibodies of the invention, as described above.
- Types of cells that may be depleted by the methods of the invention include, without limitation, plasma cells, na ⁇ ve B cells, memory B cells (including switched, unswitched, and double negative), lymphoma cells derived from B cells, and cells that express BCMA, a protein similar thereto, the extracellular domain thereof, or a polypeptide similar to the extracellular domain thereof.
- a cell may be in more than one of the foregoing categories.
- antibody-mediated cell depletion methods see “Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20”, Mitchell E. Reff, Blood , vol. 83, pp. 435-445, Jan. 15, 1994.
- treatment with an antibody of the invention reduces the number of one or more of the above-listed cell types by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, and least 85%, at least 90%, or at least 95%. In some embodiments, treatment with an antibody of the invention reduces the number of plasma cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%.
- treatment with an antibody of the invention reduces the number of switched memory B cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60%. In some embodiments, treatment with an antibody of the invention reduces the number of unswitched memory B cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60%. In some embodiments, treatment with an antibody of the invention reduces the number of double negative memory B cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60%. In some embodiments, treatment with an antibody of the invention reduces the number of naive B cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60%.
- the invention also provides methods of reducing serum immunoglobulin levels comprising administering an antibody of the invention.
- such methods reduce serum IgM levels.
- treatment with an antibody of the invention reduces serum IgM levels by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, or at least 65%.
- such methods reduce serum IgG levels.
- such methods reduce the levels of one or both of IgG2 and IgG3.
- such methods reduce the levels of IgG2 by at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 65%, or at least 70%.
- such methods reduce the levels of IgG3 by at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80%. In some embodiments, such methods reduce IgG2, IgG3, and IgM levels.
- the invention also provides methods of reducing the level of at least one autoantibody comprising administering an antibody of the invention.
- such methods reduce the level of one or more autoantibodies by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, and least 85%, at least 90%, or at least 95%.
- the invention provides methods of treating or preventing or delaying a B-cell mediated condition disorder.
- the method includes administering to a subject in which such treatment or prevention or delay is desired, an antibody of the invention in an amount sufficient to treat, prevent, or delay a tumorigenic or immunoregulatory condition in the subject.
- the subject is a human.
- the subject is a non-human mammal.
- administration of the antibody of the invention blocks BCMA-mediated signalling in the subject, which may result in one or more of cell death, inhibition, reduction, or cessation of cell proliferation.
- the antibodies or antibody fragments of the invention use BCMA to “target” B cell lymphomas.
- targeting can be generalized as follows: antibodies or antibody fragments of the invention specific to the BCMA surface antigen of B cells are, e.g., injected into a subject and specifically bind to the BCMA cell surface antigen of (ostensibly) both normal and malignant B cells; this binding leads to the destruction and/or depletion of neoplastic B cells.
- chemical agents or radioactive labels having the potential to destroy cancer cells and/or tumors can be conjugated to the antibodies or antibody fragments of the invention such that the agent is specifically “delivered” to the targeted B cells, such as, e.g., neoplastic B cells.
- the methods of the invention comprise administering an antibody or antibody fragment that is not conjugated to a chemical agent or radioactive label. In some embodiments, the methods of the invention comprise administering an antibody or antibody fragment that is not conjugated to a cytotoxic agent.
- B cell-related disorders include, without limitation, autoimmune diseases involving inappropriate B cell activity and B cell lymphomas.
- B cell lymphomas include, without limitation, multiple myeloma, plasmacytoma, Hodgkins' lymphoma, follicular lymphomas, small non-cleaved cell lymphomas, endemic Burkitt's lymphoma, sporadic Burkitt's lymphoma, marginal zone lymphoma, extranodal mucosa-associated lymphoid tissue lymphoma, nodal monocytoid B cell lymphoma, splenic lymphoma, mantle cell lymphoma, large cell lymphoma, diffuse mixed cell lymphoma, immunoblastic lymphoma, primary mediastinal B cell lymphoma, pulmonary B cell angiocentric lymphoma, and small lymphocytic lymphoma.
- the antibodies or antibody fragments of the invention may also be used to treat cancers in which the cancer cells express BCMA.
- the B cell-related disorders additionally include B cell proliferations of uncertain malignant potential, such as, for example, lymphomatoid granulomatosis and post-transplant lymphoproliferative disorder.
- the conditions diagnosed, treated, prevented or delayed using the antibodies or antibody fragments of the invention can additionally be an immunoregulatory disorder.
- immunoregulatory disorders include those that are autoimmune in nature such as, for example, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, autoimmune hemolytic anemia, idiopathic thrombocytopenia purpura, anti-phospholipid syndrome, Chagas' disease, Grave's disease, Wegener's granulomatosis, poly-arteritis nodosa, Sjogren's syndrome, pemphigus vulgaris, scleroderma, multiple sclerosis, anti-phospholipid syndrome, ANCA associated vasculitis, Goodpasture's disease, Kawasaki disease, and rapidly progressive glomerulonephritis.
- the antibodies or antibody fragments of the invention may also have application in plasma cell disorders such as heavy-chain disease, primary or immunocyte-associated amyloidosis, and monoclo
- compositions and methods of treatment using the antibodies or antibody fragments of the invention can be used with any condition associated with undesired BCMA-expressing cell proliferation.
- the antibodies of the invention may also be administered in conjunction with antibody C2B8 of U.S. Pat. No. 5,736,137, also known as RITUXANTM. In some embodiments, such combined administration depletes or inhibits the proliferation of multiple B cell subtypes.
- the invention further provides for the use of the antibodies of the invention to assay B cell phenotypes, such as determination of the presence, absence, or amount of a marker on the surface of a B cell or B cell subtype.
- the antibodies of the invention may be used to measure the presence of a marker associated with SLE or another B cell-related condition on the surface of na ⁇ ve B cells, memory B cells, IgD+ memory B cells, IgD ⁇ memory B cells, or double negative memory B cells.
- compositions suitable for administration typically comprise antibodies and a pharmaceutically acceptable carrier.
- pharmaceutically acceptable carrier is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, diluents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin.
- Liposomes and non-aqueous vehicles such as fixed oils may also be used.
- the use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the antibodies, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- a pharmaceutical composition comprising antibodies of the invention is formulated to be compatible with its intended route of administration.
- routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, and rectal administration.
- Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- the pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide.
- the parenteral preparation can be
- compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
- suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS).
- the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
- the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
- the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
- Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
- isotonic agents for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition.
- Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating antibodies of the invention in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization.
- dispersions are prepared by incorporating the antibodies into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above.
- methods of preparation are vacuum drying and freeze-drying that yields a powder of the antibodies plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- the antibodies are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
- a controlled release formulation including implants and microencapsulated delivery systems.
- Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
- the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
- Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers.
- the antibodies or antibody fragments of the invention may be used to target liposomal suspensions to B cells or subclasses thereof to which the particular antibody binds.
- B cells or subclasses thereof to which the particular antibody binds.
- These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- compositions may be formulated in dosage unit form for ease of administration and uniformity of dosage.
- Dosage unit form refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of antibody calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier.
- the specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.
- compositions comprising an antibody of the invention can be included in a container, pack, or dispenser together with instructions for administration.
- An isolated antibody that binds to SEQ ID NO:9 and binds to na ⁇ ve B cells comprising administering an antibody that binds to SEQ ID NO:9 and binds to na ⁇ ve B cells.
- the heavy chain variable domain comprises SEQ ID NO:3 and the light chain variable domain comprises SEQ ID NO:12. 19.
- Anti-BCMA monoclonal antibodies were generated by immunizing female RBF mice with BCMA-Fc/KLH conjugate protein i.p. in CFA, followed by additional immunizations at regular intervals with IFA, except that the last boost used RIBI instead of IFA, prior to splenocyte fusion to the FL653 myeloma cell line after the method of Harlow and Lane (1998), Using Antibodies: A Laboratory Manual: Portable Protocol No. I , Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Briefly, splenocytes isolated from a mouse 3 days after the final boost were washed twice and mixed in a 7:1 ratio with twice-washed log phase FL653 myeloma cells.
- the cell mixture was split four ways, pelleted, and incubated in 37° C. PEG for 1 min during which time cells were gently resuspended, followed by careful addition of 10 ml ice-cold DMEM. Cells were mixed, pelleted, and resuspended in AAT hybridoma growth selection media. Cell supernatants were screened for BCMA-specific reactivity by ELISA and flow cytometry. Clones that scored positive for BCMA and negative for Fc-specificity in an ELISA format, positive on BCMA-transfected cells, and negative on mock-transfected cells were expanded and subcloned.
- BCMA-specific clones were selected for further evaluation: C11D5.3 (IgG1), C12A3.2 (IgG1), C13F12.1 (IgG1) and A7D12.2 (IgG2b).
- Anti-BCMA mAbs were biotin-conjugated for use in ELISA and FACS experiments described below using a kit according to the manufacturer's recommendations (Molecular Probes, Eugene, Oreg.).
- Total cellular RNA from murine hybridoma cells was prepared using a Qiagen RNeasy mini kit following the manufacturer's recommended protocol.
- cDNAs encoding the variable regions of the heavy and light chains were cloned by RT-PCR from total cellular RNA, using random hexamers for priming of first strand cDNA.
- a cocktail of degenerate forward primers hybridizing to multiple murine immunoglobulin gene family signal sequences and a single back primer specific for the 5′ end of the murine constant domain were used.
- PCR was performed using Clontech Advantage 2 Polymerase mix following the manufacturer's recommended protocol.
- PCR products were gel-purified and subcloned into Invitrogen's pCR2.1TOPO vector using their TOPO cloning kit following the manufacturer's recommended protocol. Inserts from multiple independent subclones were sequenced to establish a consensus sequence. Deduced mature immunoglobulin N-termini were consistent with those determined by Edman degradation from the hybridoma. Assignment to specific subgroups was based upon BLAST analysis using consensus immunoglobulin variable domain sequences from the Kabat database (Johnson and Wu (2000), Nucleic Acids Res 28:214-218). CDRs were designated using the Kabat definitions (Johnson and Wu (2000), Nucleic Acids Res 28:214-218).
- DHFR dihydrofolate reductase
- CHO Chinese hamster ovary
- the growth medium was changed to alpha minus MEM (Gibco, Rockville, Md.), 10% dialyzed serum (Hyclone, Logan, Utah), and 2 mM L-glutamine (Gibco, Rockville, Md.), and cells were pooled and split into three T-75 tissue culture flasks and allowed to grow to confluence. Seven days post-transfection, the cells were pooled again and split into five T225 tissue culture flasks and allowed to grow to confluence.
- the highest expressing clone was used for assessing new anti-human BCMA mAbs, with untransfected CHO cells as a control. Briefly, BCMA-CHO cells were pretreated with FACS buffer plus 5% normal mouse serum to block non-specific binding sites. Seven anti-BCMA mAbs—C11D5.3, C12A3.2, C13F12.1 and A7D12.2 and the commercially available anti-BCMA mAbs, C4E2.2 (Legacy Biogen), VICKY-1 (Alexis) and 335004 (R&D Systems, Inc.)—and isotype control antibodies were incubated separately with cells for 30 minutes on ice at 1 ⁇ g/ml, and washed.
- Biotin-conjugated isotype control Abs were as follows: mouse IgG1, eBioscience cat. no. 13-4714-85; mouse IgG2a, eBioscience, cat. no. 13-4732-85; hamster IgG1, BD Pharmingen cat. no. 553970; rat IgG2a, eBioscience, cat. No. 13-4321-82.
- Streptavidin-PE (Molecular Probes, Eugene, Oreg.) was added to cells for 30 minutes on ice, after which cells were washed, fixed in 0.8% paraformaldehyde, and run on a FACScalibur flow cytometer (BDbiosciences, San Jose, Calif.) and analyzed using Flowjo software (Treestar, Ashland, Oreg.). Results are shown in FIG. 1 .
- Example 3 The seven anti-BCMA mAbs tested in Example 3 were then assessed in a cross-blocking assay to determine the presence or absence of epitope overlap between each antibody.
- Corning 96-well flat-bottom plates were incubated overnight at 4° C. with 10 ⁇ g/ml of mouse anti-human Fc in a 50 mM pH 9.6 sodium bicarbonate solution, washed, incubated with 2 ⁇ g/ml human BCMA-Fc (SEQ ID NO:10) at 37° C. for 1 hr, washed again, and non-specific binding sites were blocked with blocking buffer (3% BSA in PBS) for 30 min at 37° C.
- blocking buffer 3% BSA in PBS
- control readings in which the unconjugated and conjugated antibodies were the same were considered background levels, i.e., the absorbance from this control was subtracted from each experimental reading for that antibody. In some cases, this background subtraction resulted in slightly negative values. Although it is possible that the labeled antibody was blocked slightly more effectively by a different unconjugated antibody than by itself, these slightly negative values might also result from experimental variation. Results were then expressed as a percentage of the positive control value, i.e., the background-adjusted absorbance reading for the biotin-conjugated antibody in the absence of a competing unconjugated antibody.
- Antibodies were considered to bind the same epitope or very closely overlapping epitopes if they each reduced the other's binding (according to the fraction calculated as above) to below 20% of the positive control value. If they did not satisfy this condition, they were considered to have at least partially distinct epitopes. Table 3 shows which antibodies have at least partially distinct epitopes.
- PBMCs peripheral blood mononuclear cells
- FACS buffer containing 5% normal mouse serum to block non-specific binding sites.
- fluorphore-conjugated monoclonal antibodies directed against specific B cell and plasma cell markers were used: anti-CD19-PE-Cy5, anti-IgD-FITC, anti-CD27-APC, anti-CD38-PE-Cy7 (BD Biosciences, San Jose, Calif.).
- Streptavidin-PE (Molecular Probes, Eugene, Oreg.) was used to visualize biotin-conjugated anti-BCMA mAbs (10 ⁇ g/ml). Binding of an isotype control mAb as in Example 3 was also measured.
- FIGS. 3A-D show a comparison between samples from a healthy volunteer and a representative SLE patient.
- Antibody A7D12.2 bound to plasma cells from both healthy volunteers and SLE patients ( FIG. 3A ).
- the A7D12.2 antibody bound na ⁇ ve B cells ( FIG. 3E ). Binding of the A7D12.2 antibody to memory B cells ( FIGS. 3B-3D ), particularly double negative memory B cells ( FIG. 3D ), was increased in SLE samples.
- CHO-DG44-I a dhfr-deficient, insulin-independent Chinese hamster ovary cell line
- the host cells were cultured in CHO-S-SFM II medium with nucleosides prior to transfection.
- Chimeric antibodies were produced by transfecting cells with expression plasmids encoding the mature heavy and light chain sequences listed in Table 4.
- Chimeric anti-BCMA expression plasmids were transfected into the CHO host cell line DG44-I using a cationic lipid (Fugene HD) method. Briefly, 1 ⁇ 10 6 DG44-I cells were seeded in each of two wells of a 6-well plate containing 3 mL of CHO-S-SFMII medium w/nucleosides per well. Four ⁇ g of plasmid DNA (2 ⁇ g heavy chain, 2 ⁇ g light chain) was diluted into 200 ⁇ L CHO-S-SFM II (Invitrogen) medium at room temperature. Sixteen ⁇ L of Fugene HD (Roche) reagent and allowed to complex with the DNA for approximately 15 minutes.
- Fugene HD Fugene HD
- CHO-DG44-I cells stably transfected with chimeric heavy and light chains were fermented in CHOM39 media, harvested, and the cells were removed by centrifugation. The pH of the cleared media was adjusted prior to passing through a protein A Fast Flow column.
- Antibodies were eluted with 100 mM Na-citrate buffer, pH 3.0, neutralized to pH 7.0 using 10% (v/v) of 2M glycine, pH 8.9, and the recovered antibody solution was buffer-exchanged to PBS (pH 7.2) using a Superdex 200 size exclusion chromatography under endotoxin-free conditions. The purified protein was kept at ⁇ 80° C.
- JJN-3 human plasmacytoma cells (DSMZ ACC 541) were cultured in culture medium consisting of 40% Dulbecco's MEM, 40% Iscove's MDM, 20% FBS, 100 units/mL penicillin and 100 ⁇ g/mL streptomycin.
- U266 human plasmacytoma cells (ATCC TIB 196) were cultured in culture medium consisting of RPMI 1640, 15% FBS, 20 mM HEPES, 100 units/mL penicillin and 100 ⁇ g/mL streptomycin. All cells were cultured at 37° C. in a 5% CO2 atmosphere.
- Peripheral blood mononuclear cells were isolated from a consented normal healthy donor by density centrifugation through Ficoll—Paque PLUS (GE Healthcare, Uppsala, Sweden).
- ADCC Antibody-Dependent Cellular Cytotoxicity
- Assay diluent was RPMI 1640, 1% BSA, 20 mM HEPES, 100 units/mL penicillin and 100 ⁇ g/mL streptomycin.
- Human plasmacytoma cell lines JJN-3 and U266 were washed and resuspended in assay diluent to 0.4 ⁇ 10 6 cells per mL. 50 ⁇ L of each cell suspension was plated into a 96-well U bottom microtiter plate in triplicates.
- Controls included target cells alone (spontaneous LDH release), target cells alone with 2% Triton X-100 in assay diluent (maximum LDH release), effector cells with and without target cells, and human IgG1 isotype control.
- PBMCs peripheral blood mononuclear cells
- chimeric mAbs C12A3.2 and C13F12.1 demonstrated marked ADCC activity relative to HIgG1 controls.
- Chimeric clones A7D12.2 and C11D5.3 also mediated ADCC, although to a lesser degree than C12A3.2 and C13F12.1.
- ADCC assays were also performed using a second BCMA+ plasmacytoma cell line, JJN-3, as the target cells. As shown in Table 6, chimeric C12A3.2, C13F12.1, and A7D12.2 also mediated ADCC of JJN-3 cells.
- NK cells were not the effector cells for chC12A3.2, chC13F12.1, or chA7D12.2 in the ADCC assays with U266 and JJN3 as target cells (data not shown).
- Generation of afucosyl variants of chC12A3.2, chC13F12.1, or chA7D12.2 did not improve activity of these mAbs (data not shown).
- HSC/NSG mice provide a useful tool for testing in vivo biologic reagents specific for human protein targets since their immune system consists of functioning human cell types (Brehm et al. (2010), Clin Immunol [Epub ahead of print]). Humanized mice were generated as previously described (Pearson et al. (2008), Curr Protoc Immunol Chapter 15:Unit 15.21.PMID: 18491294). NOD/SCID/common gamma chain-deficient mice (NSG mice) were purchased from Jackson Laboratories (Bar Harbor, Me.). Mice were maintained and bred under specific-pathogen-free conditions in isolator cages. Breeding pairs were established and dams were monitored for pregnancy and delivery.
- Pups ranging in age from 2-6 days old were used to create humanized mice. Pups were lightly irradiated, receiving a dose of 1 Gy (100 rad) from a 137Cs irradiator. Pups were immediately injected intra-orbitally with approximately 50,000 CD34+CD3 ⁇ human stem cells (HSC) derived from umbilical cord blood (All Cell LLC, purchased from StemCell Technologies Inc., Vancouver, BC, Canada), then returned to the dam. Pups were weaned at 21 days and caged with littermates according to gender. Starting at 3 months of age mice were bled via the facial vein into heparinized tubes and the whole blood was analyzed by flow cytometry for the presence of human cells.
- HSC human stem cells
- mice were considered successfully humanized if they had at least 20% human CD45+ cells in whole blood of which 10% or more were human CD3+, the remainder being human B cells and other human hematopoietic cells. Mice were occasionally bled and analyzed to ensure that the humanization was stable, and were routinely analyzed 2 weeks prior to study enrollment.
- PC plasma cells
- HSC/NSG human stem cell humanized NSG mice
- HSC/NSG human stem cell humanized NSG mice
- mAbs directed to human cell lineage and to human B cell markers.
- the panel consisted of anti-human CD45, anti-human CD19, anti-human CD27, anti-human IgD, and anti-human CD38.
- Two markers used to exclude specific cell populations were anti-mouse CD45 and anti-human CD3.
- Cells identified as PC were human CD45+, human CD19+, human CD3-, human CD27+, human IgD- and human CD38bright.
- BCMA+ cells the biotin-conjugated anti-human BCMA mAbs, C12A3.2 and A7D12.2, were used.
- mice received chimeric anti-BCMA mAb i.p. Human IgG1 with no known reactivity (Protos Immunoresearch) was used as a negative control. Blood was collected to prepare serum for analysis of human Ig isoform levels. At the study terminus the spleen was harvested, a single cell suspension was prepared, RBCs were lysed and cells were washed 3 ⁇ with PBS/5% FCS and the cell number was determined. Cells were assessed by flow cytometry for T lineage cells, B lineage cells, and plasma cells.
- Serum levels of human IgM and IgG were determined using an ELISA format (Bethyl Laboratories Inc., Montgomery, Tex.) and a human immunoglobulin isotyping kit (Millipore, Billerica, Mass.), respectively, according to the manufacturer's protocol.
- BCMA+ cells were only found in the B cell lineage.
- BCMA was found only on splenic PCs (human CD19+, human CD27+, IgD ⁇ , CD38 bright) ( FIG. 4 ), and not on na ⁇ ve B cells (human CD19+, human CD27 ⁇ , IgD+), unswitched memory B cells (human CD19+, human CD27+, human IgD+), or switched memory B cells (human CD19+, human CD27+, human IgD ⁇ ) (data not shown).
- HSC/NSG mice received various amounts of chimeric anti-human BCMA clones chAC11D5.3, chC12A3.2, chC13F12.1, and chA7D12.2 (Example 7) twice weekly i.p. for 2 weeks, after which the presence of splenic PCs was determined.
- Splenic PCs from the HIgG1-treated control group were analyzed for expression of BCMA using the A7D12.2 and C12A3.2 clones and were confirmed to express cell surface BCMA (data not shown).
- PCs were identified using the flow cytometric parameters described above, and total cell numbers were determined from the flow cytometric dot plots (calculated as a percentage of the total human cell number). The numbers of na ⁇ ve human B cells, unswitched memory human B cells, and switched memory human B cells were also determined.
- Treatment with chC13F12.1 resulted in a statistically significant decline, 88% and 51° A, in the number of splenic PCs at the 200 ⁇ g and 20 ⁇ g dose levels, respectively ( FIG. 5 ). No impact on the number of other B cell subsets or T cells was observed with chC12A3.2 and chC13F12.1 (data not shown).
- BCMA could not be detected on the surface of switched memory B cells in untreated humanized mice, it appears that while the level of BCMA was below the limit of detection by flow cytometry, it was sufficient to result in Ab-mediated killing.
- Chimeric C12A3.2 resulted in a 63%, 62% and 30% reduction in IgM for the 200, 20 and 2 ⁇ g dose levels, respectively.
- Chimeric C13F12.1 resulted in a 52%, 42% and 32% reduction in IgM for the 200, 20 and 2 ⁇ g dose levels, respectively.
Abstract
Description
- This application is a continuation of U.S. patent application Ser. No. 16/026,242, filed Jul. 3, 2018, which is a continuation of U.S. patent application Ser. No. 15/065,641, filed Mar. 9, 2016, abandoned, which is a continuation of U.S. patent application Ser. No. 14/596,769, filed Jan. 14, 2015, abandoned, which is a continuation of U.S. patent application Ser. No. 13/255,610, filed Nov. 23, 2011, now U.S. Pat. No. 9,034,324, which issued May 19, 2015, which is a National Stage Entry of PCT/US2010/026825, filed Mar. 10, 2010, expired, which claims the benefit of U.S. Provisional Application No. 61/162,924, filed Mar. 24, 2009, expired, and U.S. Provisional Application No. 61/158,942, filed Mar. 10, 2009, expired. All of these applications are incorporated herein by reference in their entirety.
- The instant application contains a Sequence Listing which has been submitted via EFS-Web and is hereby incorporated by reference in its entirety. The ASCII copy, created on Mar. 10, 2010, is named 08201010.txt, and is 70,657 bytes in size.
- This invention relates to antibodies that bind to the B cell surface antigen BCMA. The invention also relates to the use of these antibodies to detect, deplete, and otherwise manipulate various B cell subtypes.
- B cells are lymphocytes that play major roles in adaptive humoral immunity and production of antibodies that specifically recognize antigens. Three subclasses of B cells are naïve B cells, memory B cells, and plasma cells. The processes of VDJ recombination, in which two or three segments of DNA are chosen from a genomic library and recombined to generate a combinatorial array of antibody variable domains, and hypermutation, by which the variable domains encoded by different lineages of B cells are further varied, result in up to 109 distinct B cell lineages that produce antibodies with specificity for distinct targets. A B cell is said to be specific for an antigen that binds the antibodies made by that B cell. B cells in general are stimulated by exposure to their specific antigen (Ag). Naïve B cells have not yet been exposed to their specific antigen. Such exposure (e.g., during an infection) results in proliferation of B cells and generation of sister clones. Sister clones can develop into plasma cells, which produce high amounts of antibody. Plasma cells may either be short lived, or may migrate into bone marrow, where they can persist for an extended period of time. A sister clone of an Ag-exposed B cell may also develop into a memory B cell that is quiescent until reexposed to the specific antigen. Memory B cells respond rapidly to reexposure to antigen by dividing to produce both plasma cells and additional memory B cells. Memory B cells include switched memory B cells (CD19+ CD27highCD38low IgD−), unswitched memory B cells (CD19+CD27highCD38low IgD+), and double negative memory B cells (CD19+CD27−CD38low IgD−).
- Several significant diseases involve B cells. Malignant transformation of B cells leads to cancers, including some lymphomas such as, for example, multiple myeloma and Hodgkins' Lymphoma. Some autoimmune diseases, including systemic lupus erythematosus (SLE), also involve B cells. Both cancer and autoimmune diseases that involve B cells may be considered gain of function conditions, in that the B cells overgrow and/or attack parts of the body inappropriately. A possible strategy to control such diseases is to use antibodies that target the pathological B cells.
- The B cell maturation antigen (BCMA, also known as TNFRSF17 and CD269) is a protein that has been shown to be expressed on the surface of plasmablasts (i.e., plasma cell precursors) and plasma cells, and is believed to stimulate survival. It therefore represents a potential target for B cell-related diseases. BCMA is a member of the TNF receptor family and binds the TNF family ligands BAFF and APRIL (reviewed in Kalled et al. (2005), Curr Dir Autoimmun 8:206-242). BCMA is a type III membrane protein, as it lacks the signal peptide associated with type I membrane proteins found in most TNF receptor family members.
- BCMA RNA has been detected in the spleen, lymph nodes, thymus, adrenals and liver, and analysis of a number of B cell lines indicated that BCMA mRNA levels increased upon maturation. Human BCMA protein has been detected on various subtypes of CD38+ B cells, particularly plasma cells (Zhang et al. (2005), Int Immunol 17:779-788; Darce et al. (2007), J Immunol 179:7276-7286; Sims et al. (2005), Blood 105:4390-4398; Avery et al. (2003), J Clin Invest 112:286-297). Independent laboratories have examined blood and/or tonsil B cell subsets and found that BCMA expression could not be detected on naïve or memory B cells (Zhang et al. (2005), Int Immunol 17:779-788; Darce et al. (2007), J Immunol 179:7276-7286; Chiu et al. (2007), Blood 109:729-739). Attempts to detect BCMA protein on the surface of germinal center B cells have had inconsistent results (Zhang et al. (2005), Int Immunol 17:779-788; Chiu et al. (2007), Blood 109:729-739).
- The mechanism of action of BCMA is not fully understood. Mice that have been genetically altered to lack a functional gene for BCMA have normal lymphoid organs and cell populations, and a nearly normal functioning immune system (Xu and Lam (2001), Mol Cell Biol 21:4067-4074; Schiemann et al. (2001), Science 293:2111-2114). The only defect defined to date in these mice is a diminished survival of long-lived bone marrow (BM) plasma cells (O'Connor et al. (2004), J Exp Med 199:91-98). Therefore, it may be that BCMA, at least in the murine system, provides a survival signal to BM-resident plasma cells that is either BAFF or APRIL-mediated, or both. Indeed, signalling through BCMA activates the NF-κB pathway (Hatzoglou et al. (2000), J Immunol 165:1322-1330) which is involved in B cell survival, proliferation and maturation (Litinskiy et al. (2002) Nat Immunol 3:822-829; Pomerantz and Baltimore (2002) Mol Cell 10:693-695; Huang et al. (2004) Proc Natl Acad Sci USA 101:17789-17794; He et al. (2004) J Immunol 172:3268-3279). Results with malignant human cells are generally consistent with a link between BCMA and cell survival. Primary multiple myeloma (MM) cells, MM cell lines (Novak et al. (2004) Blood 103:689-694), and Hodgkin and Reed-Sternberg (HRS) cells from Hodgkin lymphomas (Chiu et al. (2007), Blood 109:729-739; Novak et al. (2004), Blood 104:2247-2253) have been shown to express BCMA. Addition of BAFF and/or APRIL has further been shown to provide a survival signal for these malignant cells, although it is not clear that BCMA is predominantly responsible for this effect.
- Because different B cell subsets are implicated in different B cell related conditions, there exists a need for agents that specifically target one or more B cell subsets. The expression of BCMA on the surface of some B cells provides a marker by which those cells may be specifically targeted. To take advantage of BCMA as a marker of one or more B cell subsets, there is a need for agents that specifically bind to BCMA and for a determination of which B cell subsets are bound by those BCMA-specific agents. The invention provides antibodies that specifically bind to BCMA. The antibodies of the invention may be used to target one or more of the following B cell subsets: plasma cells, memory B cells, and naïve B cells.
-
FIGS. 1A-1C depict_binding of anti-human BCMA mAbs on BCMA-transfected CHO cells. Binding of biotin-conjugated anti-human BCMA mAbs, visualized with Streptavidin-PE, was measured by flow cytometry on a BCMA-CHO stable cell line (FIG. 1A ) and control, non-transfected CHO cells (FIG. 1B ). The shaded area represents staining of cells with an isotype control mAb. -
FIGS. 2A-2F depict anti-BCMA binding to B cell subsets. B cell subsets in human peripheral blood were assessed by flow cytometry for reactivity to anti-BCMA mAbs. Visualization was as inFIG. 1 . The shaded area represents staining with an isotype control Ab. B cell subsets were plasma cells (CD19+CD27highCD38highIgD−) (FIG. 2A ), switched memory B cells (CD19+CD27highCD38low IgD−) (FIG. 2B ), unswitched memory B cells (CD19+CD27highCD38low IgD+) (FIG. 2C ), double negative memory B cells (CD19+CD27−CD38low IgD−) (FIG. 2D ), and naïve B cells (CD19+CD27−IgD+) (FIG. 2E ). -
FIGS. 3A-3D depict anti-BCMA binding to B cell subsets isolated from healthy and SLE-afflicted individuals. B cell subsets in human peripheral blood from a healthy volunteer and an SLE patient were assessed by flow cytometry for reactivity to the anti-BCMA mAbs C12A3.2 and A7D12.2. B cell subsets were as inFIG. 2 . Visualization was as inFIG. 1 . -
FIG. 4 depicts flow cytometric staining of human plasma cells within the human CD45+ splenocyte compartment isolated from HSC/NSG mice. Splenic plasma cells were stained with anti-BCMA antibodies A7D12.2 (left panel; bold line) and C12A3.2 (right panel; bold line) or an isoytpe control mouse IgG2b or IgG1 Ab, respectively (thin line in both panels). -
FIG. 5 depicts flow cytometric staining for plasma cells (PCs) within the human CD45+ splenocyte compartment isolated from HSC/NSG mice treated with anti-BCMA antibody (chC12A3.2 or chC13F12.1) or human IgG1 control. Mice were injected i.p. with anti-BCMA Ab or HIgG1 control twice weekly for 2 weeks. ** p<0.0001;* p=0.0066. -
FIG. 6 depicts flow cytometric staining for plasma cells (PCs) within the human CD45+ splenocyte compartment isolated from HSC/NSG mice treated with anti-BCMA antibody (chC11D5.1 or chA7D12.2) or human IgG1 control. Mice were injected i.p. with anti-BCMA Ab or HIgG1 control twice weekly for 2 weeks. -
TABLE 1 Brief Description of the Sequences SEQ ID NO Description of sequence 1 A7D12.2 mature heavy chain variable domain protein sequence 2 A7D12.2 mature light chain variable domain protein sequence 3 C11D5.3 mature heavy chain variable domain protein sequence 4 C11D5.3 mature light chain variable domain protein sequence A 5 C12A3.2 mature heavy chain variable domain protein sequence 6 C12A3.2 mature light chain variable domain protein sequence 7 C13F12.1 mature heavy chain variable domain protein sequence 8 C13F12.1 mature light chain variable domain protein sequence 9 BCMA protein sequence 10 huBCMA-huFc (as defined by N-terminal sequence analysis) 11 C11D5.3 mature light chain variable domain protein sequence B 12 C11D5.3 mature light chain variable domain protein sequence C 13 chA7D12.2 chimeric mature heavy chain protein sequence 14 chA7D12.2 chimeric mature light chain protein sequence 15 chC11D5.3 chimeric mature heavy chain protein sequence 16 chC11D5.3 chimeric mature light chain protein sequence A 17 chC11D5.3 chimeric mature light chain protein sequence C 18 chC12A3.2 chimeric mature heavy chain protein sequence 19 chC12A3.2 chimeric mature light chain protein sequence 20 chC13F12.1 chimeric mature heavy chain protein sequence 21 chC13F12.1 chimeric mature light chain protein sequence 22 huC11D5.3L1 humanized mature light chain variable domain sequence 23 huC11D5.3L2 humanized mature light chain variable domain sequence 24 huC11D5.3L3 humanized mature light chain variable domain sequence 25 huC11D5.3H0 humanized mature heavy chain variable domain sequence 26 huC11D5.3H1 humanized mature heavy chain variable domain sequence 27 huC11D5.3H2 humanized mature heavy chain variable domain sequence 28 huC11D5.3H3 humanized mature heavy chain variable domain sequence 29 huC11D5.3H4 humanized mature heavy chain variable domain sequence 30 huC12A3.2L0 humanized mature light chain variable domain sequence 31 huC12A3.2L1 humanized mature light chain variable domain sequence 32 huC12A3.2L2 humanized mature light chain variable domain sequence 33 huC12A3.2L3 humanized mature light chain variable domain sequence 34 huC12A3.2H0 humanized mature heavy chain variable domain sequence 35 huC12A3.2H1 humanized mature heavy chain variable domain sequence 36 huC12A3.2H2 humanized mature heavy chain variable domain sequence 37 huC12A3.2H3 humanized mature heavy chain variable domain sequence 38 huC12A3.2H4 humanized mature heavy chain variable domain sequence 39 huC13F12.1L0 humanized mature light chain variable domain sequence 40 huC13F12.1L1 humanized mature light chain variable domain sequence 41 huC13F12.1L2 humanized mature light chain variable domain sequence 42 huC13F12.1L3 humanized mature light chain variable domain sequence 43 huC13F12.1H0 humanized mature heavy chain variable domain sequence 44 huC13F12.1H1 humanized mature heavy chain variable domain sequence 45 huC13F12.1H2 humanized mature heavy chain variable domain sequence 46 huC13F12.1H3 humanized mature heavy chain variable domain sequence 47 huC13F12.1H4 humanized mature heavy chain variable domain sequence - The invention provides antibodies that bind to BCMA and certain epitopes thereof. In some embodiments, the antibodies of the invention bind to one or more subsets of B cells, such as plasma cells, memory B cells, and naïve B cells. The invention also provides methods of depleting B cells or subclasses of B cells, including plasma cells, memory B cells, and naïve B cells. In one embodiment, the invention provides an isolated antibody that binds to SEQ ID NO:9 and binds to plasma cells. In one embodiment, the invention provides an isolated antibody that binds to SEQ ID NO:9 and binds to memory B cells. In another embodiment, the invention provides an isolated antibody that binds to SEQ ID NO:9 and binds to naïve B cells.
- Certain anti-BCMA mAbs, including clone C4E2.2 (hamster IgG) generated at Legacy Biogen (6); clone VICKY-1 (rat IgG1) (Alexis Biochemicals, Lausen, Switzerland, also sold as 6D10 by Santa Cruz Biotechnology, Santa Cruz, Calif.); and clone 335004 (rat IgG2a) (R&D Systems, Inc., Minneapolis, Minn.), are outside the scope of this invention.
- A. Antibodies
- The invention provides antibodies that bind specifically to SEQ ID NO:9. The invention also provides to antibodies that bind to the surface of B cells or subclasses thereof, including plasma cells, memory B cells (including switched, unswitched, and double negative), and/or naïve B cells. The term “antibody” as used herein, includes both full-length immunoglobulins and antibody fragments that bind to the same antigens. The antibodies can be, e.g., a monoclonal, polyclonal, chimeric, humanized, or single chain antibody. In some embodiments, the antibody fragments are Fab fragments or F(ab′)2 fragments and retain the ability to specifically bind the protein of SEQ ID NO: 9.
- In part, the invention provides the antibodies A7D12.2, C11D5.3, C12A3.2, and C13F12.1. Each of these is a murine monoclonal antibody. A7D12.2 has a murine “miscellaneous” subgroup heavy chain, a heavy chain variable domain sequence that is SEQ ID NO:1, a subgroup I kappa light chain, and a light chain variable domain sequence that is SEQ ID NO:2.
- C11D5.3 has a subgroup II (A) heavy chain, a heavy chain variable domain sequence that is SEQ ID NO:3, a murine subgroup III kappa light chain, and a light chain variable domain sequence that is selected from SEQ ID NO:4, SEQ ID NO:11, and SEQ ID NO:12. In some embodiments, the light chain variable domain sequence of C11D5.3 is SEQ ID NO:12.
- C12A3.2 has a subgroup II (A) heavy chain, a heavy chain variable domain sequence that is SEQ ID NO:5, a murine subgroup III kappa light chain, and a light chain variable domain sequence that is SEQ ID NO:6.
- C13F12.1 has a subgroup II (A) heavy chain, a heavy chain variable domain sequence that is SEQ ID NO:7, a murine subgroup III kappa light chain, and a light chain variable domain sequence that is SEQ ID NO:8.
- Techniques for producing single-chain antibodies specific to the protein of SEQ ID NO: 9 can be adapted from e.g., those described in U.S. Pat. No. 4,946,778. In addition, methods can be adapted for the construction of Fab expression libraries (see e.g., Huse et al. (1989) Science 246:1275-1281) to allow rapid and effective identification of monoclonal Fab fragments with the desired specificity for a BCMA protein or derivatives, fragments, analogs or homologs thereof. Numerous techniques for humanizing non-human antibodies are well known in the art. See e.g., U.S. Pat. Nos. 5,225,539, 6,632,927, or 5,648,237, all of which are incorporated by reference. Antibody fragments that contain the idiotypes to a BCMA protein may be produced by any of a variety of techniques, including, but not limited to: (i) an F(ab′)2 fragment produced by pepsin digestion of an antibody molecule; (ii) an Fab fragment generated by reducing the disulfide bridges of an F(ab′)2 fragment; (iii) a Fab fragment generated by the treatment of the antibody molecule with papain and a reducing agent and (iv) Fv fragments.
- Additionally, recombinant anti-BCMA antibodies, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, are within the scope of the invention. Such chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques such as, for example, the methods described in U.S. Pat. No. 7,112,421; Better et al. (1988) Science 240:1041-1043; or Liu et ai. (1987) Proc. Natl. Acad. Sci. USA 84:3439-3443.
- Some of the antibodies of the invention are chimeric forms of murine monoclonal antibodies A7D12.2, C11D5.3, C12A3.2, and C13F12.1. In some embodiments, a chimeric form of A7D12.2 comprises a heavy chain comprising SEQ ID NO:13 and a light chain comprising SEQ ID NO:14. In some embodiments, a chimeric form of C11D5.3 comprises a heavy chain comprising SEQ ID NO:15 and a light chain comprising a sequence selected from SEQ ID NO:16 and SEQ ID NO:17, preferably SEQ ID NO:17. In some embodiments, a chimeric form of C12A3.2 comprises a heavy chain comprising SEQ ID NO:18 and a light chain comprising SEQ ID NO:19. In some embodiments, a chimeric form of C13F12.1 comprises a heavy chain comprising SEQ ID NO:20 and a light chain comprising SEQ ID NO:21.
- Some of the antibodies of the invention are humanized forms of murine monoclonal antibodies A7D12.2, C11D5.3, C12A3.2, and C13F12.1. In some embodiments, a humanized form of C11D5.3 comprises a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 22-24 and a heavy chain variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 25-29. In some embodiments, a humanized form of C12A3.2 comprises a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 30-33 and a heavy chain variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 34-38. In some embodiments, a humanized form of C13F12.1 comprises a light chain variable domain comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 39-42 and a heavy chain variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, at least 95%, or 100% identical to a sequence selected from SEQ ID NOs 43-47.
- B. Antibody Variable Domain Sequence
- The antibodies of the invention may comprise the heavy chain variable domain sequences of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. The heavy chain variable domain sequences may consist essentially of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.
- The antibodies of the invention may comprise the light chain variable domain sequences of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12. The light chain variable domain sequences may consist essentially of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12.
- The invention also provides a variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to a sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7. The invention also provides a variable domain sequence comprising a sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to a sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, and SEQ ID NO:12. The invention also provides antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:1 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:2. The invention includes antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:3 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO: 4, SEQ ID NO:11, or SEQ ID NO:12. The invention includes antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:5 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:6. The invention includes antibodies comprising a heavy chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:7 and a light chain variable domain sequence that is at least 80%, at least 85%, at least 90%, or at least 95% identical to SEQ ID NO:8.
- The invention also provides antibodies with particular complementarity determining regions (CDR). Table 2 defines the amino acid coordinates of CDR1, CDR2, and CDR3 of SEQ ID NOs:1 through 8, 11, and 12.
-
TABLE 2 CDR Amino Acid Coordinates SEQ ID NO Description CDR1 CDR2 CDR3 1 A7D12.2 VH 31-35 50-66 99-111 2 A7D12.2 VL 24-34 50-56 89-97 3 C11D5.3 VH 31-35 50-66 99-106 4 C11D5.3 VL A 24-38 54-60 93-101 5 C12A3.2 VH 31-35 50-66 99-106 6 C12A3.2 VL 24-38 54-60 93-101 7 C13F12.1 VH 31-35 50-66 99-106 8 C13F12.1 VL 24-38 54-60 93-101 11 C11D5.3 VL B 24-38 54-60 93-101 12 C11D5.3 VL C 24-38 54-60 93-101 - CDRs are designated using the Kabat definitions (Johnson and Wu (2000), Nucleic Acids Res 28:214-218). As used herein, the “corresponding CDR” means the CDR in the most similar position within the variable domain amino acid sequence.
- The heavy chain variable domain of antibodies of the invention may comprise CDRs such that one, two, or three of the CDRs are identical to the corresponding CDRs of SEQ ID NO:1; identical to the corresponding CDRs of SEQ ID NO:3; identical to the corresponding CDRs of SEQ ID NO:5; or identical to the corresponding CDRs of SEQ ID NO:7. The light chain variable domain of antibodies of the invention may comprise CDRs such that one, two, or three of the CDRs are identical to the corresponding CDRs of SEQ ID NO:2; identical to the corresponding CDRs of SEQ ID NO:4; identical to the corresponding CDRs of SEQ ID NO:6; identical to the corresponding CDRs of SEQ ID NO:8; identical to the corresponding CDRs of SEQ ID NO:11; or identical to the corresponding CDRs of SEQ ID NO:12.
- The heavy chain variable domain may comprise CDRs identical to each of the corresponding CDRs of one of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7 except that one or more amino acid substitutions have been made in said CDR regions. In certain embodiments, CDRs of the heavy chain variable domain may have up to a total of 12 amino acid substitutions relative to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In other embodiments, the heavy chain variable domain CDRs of the antibodies of the invention may have up to 10, up to 8, up to 5, or up to 3 substitutions relative to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7. In some embodiments, the heavy chain variable domain CDRs of the antibodies of the invention are at least 80%, at least 85%, at least 90%, or at least 95% identical to the heavy chain variable domain CDRs of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.
- In some embodiments, CDR2 of SEQ ID NO:7 is replaced by CDR2 (i.e., amino acids 50-66) of SEQ ID NO:46. For example, the heavy chain variable domain of an antibody of the invention may comprise CDR1 and CDR3 of SEQ ID NO:7 and CDR2 of SEQ ID NO:46. The heavy chain variable domain of an antibody of the invention may also comprise CDR1, CDR2, and CDR3 regions that are together at least 80%, at least 85%, at least 90%, or at least 95% identical to CDR1 and CDR3 of SEQ ID NO:7 and CDR2 of SEQ ID NO:46.
- The light chain variable domain may comprise CDRs identical to the corresponding CDRs of one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12, except for one or more amino acid substitutions in said CDR regions. In certain embodiments, the antibodies of the invention comprise CDRs that are identical to the corresponding CDRs of one of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12, except for up to 12, up to 10, up to 8, up to 5, or up to 3 amino acid substitutions in said CDR regions. In some embodiments, the light chain variable domain CDRs of the antibodies of the invention are at least 80%, at least 85%, at least 90%, or at least 95% identical to the light chain variable domain CDRs of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8, SEQ ID NO:11, or SEQ ID NO:12.
- In some embodiments, the substitutions in the CDR regions are conservative substitutions.
- C. Epitopes; Antibody Binding Specificity
- The invention also provides antibodies that bind particular epitopes. Whether a pair of antibodies binds the same epitope is determined based on cross-blocking experiments, as described in Example 4. Cross-blocking profiles are defined for seven antibodies in Table 3. For the purposes of this disclosure, two antibodies are considered to bind to the same epitope if each one reduces the other's binding to BCMA (i.e., they mutually cross-block) by at least 90% according to the procedure described in Example 4. Similarly, antibodies that do not reduce each other's binding by at least 90% as described in Example 4 are considered to bind to distinct epitopes. The cross-blocking profiles of antibodies with certain variable domains are listed in Table 3. Pairs of antibodies that bind to distinct epitopes (as defined above) are noted with a “d.”
-
TABLE 3 Cross-Blocking Profiles Heavy chain Light chain var. domain var. domain Distinct (d) from epitope bound by: SEQ ID NO SEQ ID NO Example C12A3.2 C11D5.3 C13F12.1 335004 C4E2 A7D12.2 VICKY-1 1 2 A7D12.2 d d d d d — d 3 12 C11D5.3 — — — d d d d 5 6 C12A3.2 — — — d d d d 7 8 C13F12.1 — — — d d d d - The invention further encompasses antibodies that bind to the same epitope as antibodies A7D12.2, C11D5.3, C12A3.2, or C13F12.1. The invention also provides antibodies that have cross-blocking profiles that match the profiles of A7D12.2, C11D5.3, C12A3.2, or C13F12.1. For example, following the definitions provided above, an antibody that has the same profile as C11D5.3 binds to the same epitope as compared to C12A3.2 and C13F12.1 but binds to a distinct epitope as compared to A7D12.2, 335004, C4E2, and Vicky-1. In some embodiments, the antibodies of the invention mutually cross-block one or more of A7D12.2, C11D5.3, C12A3.2, or C13F12.1 from binding the protein of SEQ ID NO: 9 by at least 80%, 85%, 90%, or 95%. The extent of cross-blocking is measured according to the procedure described in Example 4.
- In some embodiments, the antibodies and antibody fragments of the invention bind to the extracellular domain of BCMA. In particular embodiments, the antibodies bind to amino acids 1-52, 1-51, 1-41, or 8-41 of SEQ ID NO:9.
- The invention also provides anti-BCMA antibodies that bind to one or more particular types of cell. The antibodies or antibody fragments of the invention may bind one or more of the following: plasma cells, memory B cells, naïve B cells, or cells that express BCMA (SEQ ID NO:9), a protein similar thereto, the extracellular domain thereof, or a polypeptide similar to the extracellular domain thereof.
- D. Methods
- The invention provides methods of depleting various types of cells. The methods comprise administering the antibodies of the invention, as described above. Types of cells that may be depleted by the methods of the invention include, without limitation, plasma cells, naïve B cells, memory B cells (including switched, unswitched, and double negative), lymphoma cells derived from B cells, and cells that express BCMA, a protein similar thereto, the extracellular domain thereof, or a polypeptide similar to the extracellular domain thereof. A cell may be in more than one of the foregoing categories. For an example of antibody-mediated cell depletion methods, see “Depletion of B Cells In Vivo by a Chimeric Mouse Human Monoclonal Antibody to CD20”, Mitchell E. Reff, Blood, vol. 83, pp. 435-445, Jan. 15, 1994.
- In some embodiments, treatment with an antibody of the invention reduces the number of one or more of the above-listed cell types by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, and least 85%, at least 90%, or at least 95%. In some embodiments, treatment with an antibody of the invention reduces the number of plasma cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, 50%, at least 60%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95%. In some embodiments, treatment with an antibody of the invention reduces the number of switched memory B cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60%. In some embodiments, treatment with an antibody of the invention reduces the number of unswitched memory B cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60%. In some embodiments, treatment with an antibody of the invention reduces the number of double negative memory B cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60%. In some embodiments, treatment with an antibody of the invention reduces the number of naive B cells by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, or at least 60%.
- The invention also provides methods of reducing serum immunoglobulin levels comprising administering an antibody of the invention. In some embodiments, such methods reduce serum IgM levels. In particular embodiments, treatment with an antibody of the invention reduces serum IgM levels by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, or at least 65%. In some embodiments, such methods reduce serum IgG levels. In some embodiments, such methods reduce the levels of one or both of IgG2 and IgG3. In some embodiments, such methods reduce the levels of IgG2 by at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 65%, or at least 70%. In some embodiments, such methods reduce the levels of IgG3 by at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 60%, at least 65%, at least 70%, at least 75%, or at least 80%. In some embodiments, such methods reduce IgG2, IgG3, and IgM levels.
- The invention also provides methods of reducing the level of at least one autoantibody comprising administering an antibody of the invention. In some embodiments, such methods reduce the level of one or more autoantibodies by at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 60%, at least 70%, at least 75%, at least 80%, and least 85%, at least 90%, or at least 95%.
- In a still further aspect, the invention provides methods of treating or preventing or delaying a B-cell mediated condition disorder. The method includes administering to a subject in which such treatment or prevention or delay is desired, an antibody of the invention in an amount sufficient to treat, prevent, or delay a tumorigenic or immunoregulatory condition in the subject. In some embodiments, the subject is a human. In other embodiments, the subject is a non-human mammal. In some embodiments, administration of the antibody of the invention blocks BCMA-mediated signalling in the subject, which may result in one or more of cell death, inhibition, reduction, or cessation of cell proliferation.
- In some embodiments, the antibodies or antibody fragments of the invention use BCMA to “target” B cell lymphomas. In essence, such targeting can be generalized as follows: antibodies or antibody fragments of the invention specific to the BCMA surface antigen of B cells are, e.g., injected into a subject and specifically bind to the BCMA cell surface antigen of (ostensibly) both normal and malignant B cells; this binding leads to the destruction and/or depletion of neoplastic B cells. Additionally, chemical agents or radioactive labels having the potential to destroy cancer cells and/or tumors can be conjugated to the antibodies or antibody fragments of the invention such that the agent is specifically “delivered” to the targeted B cells, such as, e.g., neoplastic B cells. In some embodiments, the methods of the invention comprise administering an antibody or antibody fragment that is not conjugated to a chemical agent or radioactive label. In some embodiments, the methods of the invention comprise administering an antibody or antibody fragment that is not conjugated to a cytotoxic agent.
- B cell-related disorders include, without limitation, autoimmune diseases involving inappropriate B cell activity and B cell lymphomas. B cell lymphomas include, without limitation, multiple myeloma, plasmacytoma, Hodgkins' lymphoma, follicular lymphomas, small non-cleaved cell lymphomas, endemic Burkitt's lymphoma, sporadic Burkitt's lymphoma, marginal zone lymphoma, extranodal mucosa-associated lymphoid tissue lymphoma, nodal monocytoid B cell lymphoma, splenic lymphoma, mantle cell lymphoma, large cell lymphoma, diffuse mixed cell lymphoma, immunoblastic lymphoma, primary mediastinal B cell lymphoma, pulmonary B cell angiocentric lymphoma, and small lymphocytic lymphoma. The antibodies or antibody fragments of the invention may also be used to treat cancers in which the cancer cells express BCMA. The B cell-related disorders additionally include B cell proliferations of uncertain malignant potential, such as, for example, lymphomatoid granulomatosis and post-transplant lymphoproliferative disorder.
- The conditions diagnosed, treated, prevented or delayed using the antibodies or antibody fragments of the invention can additionally be an immunoregulatory disorder. These disorders include those that are autoimmune in nature such as, for example, systemic lupus erythematosus, rheumatoid arthritis, myasthenia gravis, autoimmune hemolytic anemia, idiopathic thrombocytopenia purpura, anti-phospholipid syndrome, Chagas' disease, Grave's disease, Wegener's granulomatosis, poly-arteritis nodosa, Sjogren's syndrome, pemphigus vulgaris, scleroderma, multiple sclerosis, anti-phospholipid syndrome, ANCA associated vasculitis, Goodpasture's disease, Kawasaki disease, and rapidly progressive glomerulonephritis. The antibodies or antibody fragments of the invention may also have application in plasma cell disorders such as heavy-chain disease, primary or immunocyte-associated amyloidosis, and monoclonal gammopathy of undetermined significance (MGUS).
- Compositions and methods of treatment using the antibodies or antibody fragments of the invention can be used with any condition associated with undesired BCMA-expressing cell proliferation.
- The antibodies of the invention may also be administered in conjunction with antibody C2B8 of U.S. Pat. No. 5,736,137, also known as RITUXAN™. In some embodiments, such combined administration depletes or inhibits the proliferation of multiple B cell subtypes.
- The invention further provides for the use of the antibodies of the invention to assay B cell phenotypes, such as determination of the presence, absence, or amount of a marker on the surface of a B cell or B cell subtype. For example, the antibodies of the invention may be used to measure the presence of a marker associated with SLE or another B cell-related condition on the surface of naïve B cells, memory B cells, IgD+ memory B cells, IgD− memory B cells, or double negative memory B cells.
- E. Pharmaceutical Compositions
- The antibodies of the invention can be incorporated into pharmaceutical compositions suitable for administration. Such compositions typically comprise antibodies and a pharmaceutically acceptable carrier. As used herein, “pharmaceutically acceptable carrier” is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, diluents, and the like, compatible with pharmaceutical administration. Suitable carriers are described in the most recent edition of Remington's Pharmaceutical Sciences, a standard reference text in the field, which is incorporated herein by reference. Preferred examples of such carriers or diluents include, but are not limited to, water, saline, finger's solutions, dextrose solution, and 5% human serum albumin. Liposomes and non-aqueous vehicles such as fixed oils may also be used. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the antibodies, use thereof in the compositions is contemplated. Supplementary active compounds can also be incorporated into the compositions.
- A pharmaceutical composition comprising antibodies of the invention is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, and rectal administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid (EDTA); buffers such as acetates, citrates or phosphates, and agents for the adjustment of tonicity such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
- Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL (BASF, Parsippany, N.J.) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that easy syringeability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as mannitol, sorbitol, and sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions can be prepared by incorporating antibodies of the invention in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the antibodies into a sterile vehicle that contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, methods of preparation are vacuum drying and freeze-drying that yields a powder of the antibodies plus any additional desired ingredient from a previously sterile-filtered solution thereof.
- In one embodiment, the antibodies are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. Additionally, the antibodies or antibody fragments of the invention may be used to target liposomal suspensions to B cells or subclasses thereof to which the particular antibody binds. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
- Parenteral compositions may be formulated in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subject to be treated; each unit containing a predetermined quantity of antibody calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on the unique characteristics of the active compound and the particular therapeutic effect to be achieved.
- The pharmaceutical compositions comprising an antibody of the invention can be included in a container, pack, or dispenser together with instructions for administration.
- F. Listing of Exemplary Embodiments:
- 1. An isolated antibody that binds to SEQ ID NO:9 and binds to memory B cells.
2. The antibody ofembodiment 1, wherein the antibody also binds to plasma cells.
3. The antibody ofembodiment 1, wherein the antibody also binds to naïve B cells.
4. The antibody ofembodiment 1, wherein the antibody also binds to naïve B cells and plasma cells.
5. A method of depleting naïve B cells, memory B cells, and plasma cells, comprising administering an antibody that binds to SEQ ID NO:9 and binds to naïve B cells, memory B cells, and plasma cells.
6. A method of depleting memory B cells, comprising administering an antibody that binds to SEQ ID NO:9 and binds to memory B cells.
7. An isolated antibody that binds to SEQ ID NO:9 and binds to naïve B cells.
8. The antibody of embodiment 7, wherein the antibody binds to plasma cells.
9. A method of depleting naïve B cells, comprising administering an antibody that binds to SEQ ID NO:9 and binds to naïve B cells.
10. An isolated antibody that binds to the polypeptide of SEQ ID NO:9, wherein the antibody comprises at least one CDR chosen from CDR1, CDR2, or CDR3 of a protein sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7.
11. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of a protein sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7.
12. The antibody ofembodiment 10, wherein the antibody comprises the CDRs at CDR1, CDR2, and CDR3 of a protein sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7.
13. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 1, and the antibody further comprises a variable domain comprising at least one of a CDR1 region identical to amino acids 24-34 of SEQ ID NO:2, a CDR2 region identical to amino acids 50-56 of SEQ ID NO:2, or a CDR3 region identical to amino acids 89-97 of SEQ ID NO:2.
14. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 3, and the antibody further comprises a variable domain comprising at least one of a CDR1 region identical to amino acids 24-38 of SEQ ID NO: 12, a CDR2 region identical to amino acids 54-60 of SEQ ID NO: 12, or a CDR3 region identical to amino acids 93-101 of SEQ ID NO: 12.
15. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 5, and the antibody further comprises a variable domain comprising at least one of a CDR1 region identical to amino acids 24-38 of SEQ ID NO: 6, a CDR2 region identical to amino acids 54-60 of SEQ ID NO: 6, or a CDR3 region identical to amino acids 93-101 of SEQ ID NO: 6.
16. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 7, and the antibody further comprises a variable domain comprising at least one of a CDR1 region identical to amino acids 24-38 of SEQ ID NO: 8, a CDR2 region identical to amino acids 54-60 of SEQ ID NO: 8, or a CDR3 region identical to amino acids 93-101 of SEQ ID NO: 8.
17. The antibody ofembodiment 10, wherein the heavy chain variable domain comprises SEQ ID NO:1 and the light chain variable domain comprises SEQ ID NO:2.
18. The antibody ofembodiment 10, wherein the heavy chain variable domain comprises SEQ ID NO:3 and the light chain variable domain comprises SEQ ID NO:12.
19. The antibody ofembodiment 10, wherein the heavy chain variable domain comprises SEQ ID NO:5 and the light chain variable domain comprises SEQ ID NO:6.
20. The antibody ofembodiment 10, wherein the heavy chain variable domain comprises SEQ ID NO:7 and the light chain variable domain comprises SEQ ID NO:8.
21. An isolated antibody that binds the same epitope as the antibody of embodiment 17.
22. An isolated antibody that binds the same epitope as the antibody of any of embodiments 18-20.
23. An isolated antibody that binds to the polypeptide of SEQ ID NO:9, wherein the antibody comprises: -
- a. a variable domain comprising CDR1, CDR2, and CDR3 regions identical to the CDR1, CDR2, and CDR3 of a sequence which is chosen from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7; or
- b. a variant of the variable domain of part (a) that is otherwise identical to said variable domain except for up to a total of 10 amino acid substitutions in said CDR regions.
24. The antibody of embodiment 53, wherein the sequence is SEQ ID NO:1 and the antibody further comprises: - c. a variable domain comprising a CDR1 region identical to amino acids 24-34 of SEQ ID NO:2, a CDR2 region identical to amino acids 50-56 of SEQ ID NO:2, and a CDR3 region identical to amino acids 89-97 of SEQ ID NO:2; or
- d. a variant of the variable domain of part (c) that is otherwise identical to said variable domain except for up to a total of 10 amino acid substitutions in said CDR regions.
25. The antibody of embodiment 53, wherein the sequence is SEQ ID NO:3 and the antibody further comprises: - c. a variable domain comprising a CDR1 region identical to amino acids 24-38 of SEQ ID NO:12, a CDR2 region identical to amino acids 54-60 of SEQ ID NO:12, and a CDR3 region identical to amino acids 93-101 of SEQ ID NO:12; or
- d. a variant of the variable domain of part (c) that is otherwise identical to said variable domain except for up to a total of 10 amino acid substitutions in said CDR regions.
26. The antibody of embodiment 53, wherein the sequence is SEQ ID NO:5 and the antibody further comprises: - c. a variable domain comprising a CDR1 region identical to amino acids 24-38 of SEQ ID NO:6, a CDR2 region identical to amino acids 54-60 of SEQ ID NO:6, and a CDR3 region identical to amino acids 93-101 of SEQ ID NO:6; or
- d. a variant of the variable domain of part (c) that is otherwise identical to said variable domain except for up to a total of 10 amino acid substitutions in said CDR regions.
27. The antibody of embodiment 53, wherein the sequence is SEQ ID NO:7 and the antibody further comprises: - c. a variable domain comprising a CDR1 region identical to amino acids 24-38 of SEQ ID NO:8, a CDR2 region identical to amino acids 54-60 of SEQ ID NO:8, and a CDR3 region identical to amino acids 93-101 of SEQ ID NO:8; or
- d. a variant of the variable domain of part (c) that is otherwise identical to said variable domain except for up to a total of 10 amino acid substitutions in said CDR regions.
28. An isolated antibody that binds to the polypeptide of SEQ ID NO:9, wherein the antibody comprises at least one CDR chosen from CDR1, CDR2, or CDR3 of a protein sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8; SEQ ID NO:11; and SEQ ID NO:12.
29. The antibody ofembodiment 28, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of a protein sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:12, SEQ ID NO:6, and SEQ ID NO:8.
30. The antibody ofembodiment 28, wherein the antibody comprises the CDRs at CDR1, CDR2, and CDR3 of a protein sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:12, SEQ ID NO:6, or SEQ ID NO:8.
31. The antibody of any of embodiments 1-4, 7, 8, 10-21, or 23-30, wherein the antibody is a chimeric, humanized, or single chain antibody.
32. A hybridoma that produces the antibody of any of embodiments 1-4, 7, 8, 10-21, or 23-30.
33. A pharmaceutical composition comprising the antibody of any of embodiments 1-4, 7, 8, 10-21, or 23-30 and a pharmaceutically acceptable carrier.
34. A polypeptide that binds to SEQ ID NO:9 and comprises the antigen binding portion, Fab fragment, or F(ab′)2 fragment of the antibody of any of embodiments 1-4, 7, 8, 10-21, or 23-30.
35. A hybridoma that produces the antigen binding portion, Fab fragment, or F(ab′)2 fragment of embodiment 33.
36. A pharmaceutical composition comprising the antigen binding portion, Fab fragment, or F(ab′)2 fragment of embodiment 33 and a pharmaceutically acceptable carrier.
37. A method of depleting plasma cells, comprising administering the antibody of any of embodiments 1-4, 8, or 10-31.
38. A method of treating a B cell-related disorder, comprising administering the antibody of any one of embodiments 1-4, 8, or 10-31.
39. The method of embodiment 38, wherein the B-cell related disorder is plasmacytoma, Hodgkins' lymphoma, follicular lymphomas, small non-cleaved cell lymphomas, endemic Burkitt's lymphoma, sporadic Burkitt's lymphoma, marginal zone lymphoma, extranodal mucosa-associated lymphoid tissue lymphoma, nodal monocytoid B cell lymphoma, splenic lymphoma, mantle cell lymphoma, large cell lymphoma, diffuse mixed cell lymphoma, immunoblastic lymphoma, primary mediastinal B cell lymphoma, pulmonary B cell angiocentric lymphoma, small lymphocytic lymphoma, B cell proliferations of uncertain malignant potential, lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder, an immunoregulatory disorder, rheumatoid arthritis, myasthenia gravis, idiopathic thrombocytopenia purpura, anti-phospholipid syndrome, Chagas' disease, Grave's disease, Wegener's granulomatosis, poly-arteritis nodosa, Sjogren's syndrome, pemphigus vulgaris, scleroderma, multiple sclerosis, anti-phospholipid syndrome, ANCA associated vasculitis, Goodpasture's disease, Kawasaki disease, autoimmune hemolytic anemia, and rapidly progressive glomerulonephritis, heavy-chain disease, primary or immunocyte-associated amyloidosis, or monoclonal gammopathy of undetermined significance.
40. The method of embodiment 38, wherein the B cell-related disorder is a B cell malignancy.
41. The method of embodiment 38, wherein the B cell-related disorder is a plasma cell malignancy.
42. The method of embodiment 41, wherein the plasma cell malignancy is multiple myeloma.
43. The method of embodiment 38, wherein the B cell-related disorder is an autoimmune disease.
44. The method of embodiment 43, wherein the autoimmune disease is systemic lupus erythematosus.
45. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 1, and the antibody further comprises a variable domain comprising at least two of a CDR1 region identical to amino acids 24-34 of SEQ ID NO:2, a CDR2 region identical to amino acids 50-56 of SEQ ID NO:2, or a CDR3 region identical to amino acids 89-97 of SEQ ID NO:2.
46. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 1, and the antibody further comprises a variable domain comprising a CDR1 region identical to amino acids 24-34 of SEQ ID NO:2, a CDR2 region identical to amino acids 50-56 of SEQ ID NO:2, and a CDR3 region identical to amino acids 89-97 of SEQ ID NO:2.
47. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 3, and the antibody further comprises a variable domain comprising at least two of a CDR1 region identical to amino acids 24-38 of SEQ ID NO: 12, a CDR2 region identical to amino acids 54-60 of SEQ ID NO: 12, or a CDR3 region identical to amino acids 93-101 of SEQ ID NO: 12.
48. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 3, and the antibody further comprises a variable domain comprising a CDR1 region identical to amino acids 24-38 of SEQ ID NO: 12, a CDR2 region identical to amino acids 54-60 of SEQ ID NO: 12, and a CDR3 region identical to amino acids 93-101 of SEQ ID NO: 12.
49. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 5, and the antibody further comprises a variable domain comprising at least two of a CDR1 region identical to amino acids 24-38 of SEQ ID NO: 6, a CDR2 region identical to amino acids 54-60 of SEQ ID NO: 6, or a CDR3 region identical to amino acids 93-101 of SEQ ID NO: 6.
50. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 5, and the antibody further comprises a variable domain comprising a CDR1 region identical to amino acids 24-38 of SEQ ID NO: 6, a CDR2 region identical to amino acids 54-60 of SEQ ID NO: 6, and a CDR3 region identical to amino acids 93-101 of SEQ ID NO: 6.
51. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 7, and the antibody further comprises a variable domain comprising at least two of a CDR1 region identical to amino acids 24-38 of SEQ ID NO: 8, a CDR2 region identical to amino acids 54-60 of SEQ ID NO: 8, or a CDR3 region identical to amino acids 93-101 of SEQ ID NO: 8.
52. The antibody ofembodiment 10, wherein the at least one CDR chosen from CDR1, CDR2, or CDR3 is from SEQ ID NO: 7, and the antibody further comprises a variable domain comprising a CDR1 region identical to amino acids 24-38 of SEQ ID NO: 8, a CDR2 region identical to amino acids 54-60 of SEQ ID NO: 8, and a CDR3 region identical to amino acids 93-101 of SEQ ID NO: 8.
53. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:1 and at least one CDR chosen from CDR1, CDR2, or CDR3 of SEQ ID No:2.
54. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:3 and at least one CDR chosen from CDR1, CDR2, or CDR3 of SEQ ID No:12.
55. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:5 and at least one CDR chosen from CDR1, CDR2, or CDR3 of SEQ ID No:6.
56. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:7 and at least one CDR chosen from CDR1, CDR2, or CDR3 of SEQ ID No:8.
57. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, and CDR3 of SEQ ID NO:1 and at least one CDR chosen from CDR1, CDR2, or CDR3 of SEQ ID No:2.
58. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, or CDR3 of SEQ ID NO:3 and at least one CDR chosen from CDR1, CDR2, or CDR3 of SEQ ID No:12.
59. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, or CDR3 of SEQ ID NO:5 and at least one CDR chosen from CDR1, CDR2, or CDR3 of SEQ ID No:6.
60. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, or CDR3 of SEQ ID NO:7 and at least one CDR chosen from CDR1, CDR2, or CDR3 of SEQ ID No:8.
61. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:1 and at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID No:2.
62. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:3 and at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID No:12.
63. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:5 and at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID No:6.
64. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:7 and at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID No:8.
65. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, and CDR3 of SEQ ID NO:1 and at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID No:2.
66. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, or CDR3 of SEQ ID NO:3 and at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID No:12.
67. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, or CDR3 of SEQ ID NO:5 and at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID No:6.
68. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, or CDR3 of SEQ ID NO:7 and at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID No:8.
69. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:1 and CDRs that are CDR1, CDR2, or CDR3 of SEQ ID No:2.
70. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:3 and CDRs that are CDR1, CDR2, or CDR3 of SEQ ID No:12.
71. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:5 and CDRs that are CDR1, CDR2, or CDR3 of SEQ ID No:6.
72. The antibody ofembodiment 10, wherein the antibody comprises at least two CDRs chosen from CDR1, CDR2, or CDR3 of SEQ ID NO:7 and CDRs that are CDR1, CDR2, or CDR3 of SEQ ID No:8.
73. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, and CDR3 of SEQ ID NO:1 and CDRs that are CDR1, CDR2, or CDR3 of SEQ ID No:2.
74. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, or CDR3 of SEQ ID NO:3 and CDRs that are CDR1, CDR2, or CDR3 of SEQ ID No:12.
75. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, or CDR3 of SEQ ID NO:5 and CDRs that are CDR1, CDR2, or CDR3 of SEQ ID No:6.
76. The antibody ofembodiment 10, wherein the antibody comprises CDRs that are CDR1, CDR2, or CDR3 of SEQ ID NO:7 and CDRs that are CDR1, CDR2, or CDR3 of SEQ ID No:8.
77. An isolated antibody that mutually cross-blocks the antibody of embodiment 17 by at least 80%.
78. An isolated antibody that mutually cross-blocks at least one of the antibodies of embodiments 18-20 by at least 80%.
79. An isolated antibody that binds to the same epitope as the antibody of embodiment 18.
80. An isolated antibody that binds to the same epitope as the antibody of embodiment 19.
81. An isolated antibody that binds to the same epitope as the antibody ofembodiment 20.
82. A method of reducing the level of at least one autoantibody, comprising administering the antibody of any of embodiments 1-4, 8, and 10-31.
83. A method of reducing serum IgM level, comprising administering the antibody of any of embodiments 1-4, 8, and 10-31.
84. A method of reducing serum IgG level, comprising administering the antibody of any of embodiments 1-4, 8, and 10-31.
85. A method of reducing serum IgG2 level, comprising administering the antibody of any of embodiments 1-4, 8, and 10-31.
86. A method of reducing serum IgG3 level, comprising administering the antibody of any of embodiments 1-4, 8, and 10-31.
87. An isolated antibody that binds to the polypeptide of SEQ ID NO:9, wherein the antibody comprises a variable domain comprising CDR1, CDR2, and CDR3 regions that are together at least 95% identical to the CDR1, CDR2, and CDR3 regions of a sequence which is chosen from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, or SEQ ID NO:7.
88. The antibody of embodiment 87, wherein the sequence is SEQ ID NO:1 and the antibody further comprises a variable domain comprising CDR1, CDR2, and CDR3 regions that are together at least 95% identical to the CDR1, CDR2, and CDR3 regions of SEQ ID NO:2.
89. The antibody of embodiment 87, wherein the sequence is SEQ ID NO:3 and the antibody further comprises a variable domain comprising CDR1, CDR2, and CDR3 regions that are together at least 95% identical to the CDR1, CDR2, and CDR3 regions of SEQ ID NO:12.
90. The antibody of embodiment 87, wherein the sequence is SEQ ID NO:5 and the antibody further comprises a variable domain comprising CDR1, CDR2, and CDR3 regions that are together at least 95% identical to the CDR1, CDR2, and CDR3 regions of SEQ ID NO:6.
91. The antibody of embodiment 87, wherein the sequence is SEQ ID NO:7 and the antibody further comprises a variable domain comprising CDR1, CDR2, and CDR3 regions that are together at least 95% identical to the CDR1, CDR2, and CDR3 regions of SEQ ID NO:8.
92. An isolated antibody that binds to the polypeptide of SEQ ID NO:9, wherein the antibody comprises a light chain variable domain comprising a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs 22-24 and a heavy chain variable domain sequence comprising a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs 25-29.
93. An isolated antibody that binds to the polypeptide of SEQ ID NO:9, wherein the antibody comprises a light chain variable domain comprising a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs 30-33 and a heavy chain variable domain sequence comprising a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs 34-38.
94. An isolated antibody that binds to the polypeptide of SEQ ID NO:9, wherein the antibody comprises a light chain variable domain comprising a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs 39-42 and a heavy chain variable domain sequence comprising a sequence that is at least 95% identical to a sequence selected from SEQ ID NOs 43-47.
95. The method of embodiment 39, wherein the B-cell related disorder is rheumatoid arthritis.
96. The method of embodiment 39, wherein the B-cell related disorder is idiopathic thrombocytopenia purpura, or myasthenia gravis, or autoimmune hemolytic anemia.
97. The method of embodiment 37, further comprising administering RITUXAN™
98. The method of embodiment 38, further comprising administering RITUXAN™
- Anti-BCMA monoclonal antibodies (mAbs) were generated by immunizing female RBF mice with BCMA-Fc/KLH conjugate protein i.p. in CFA, followed by additional immunizations at regular intervals with IFA, except that the last boost used RIBI instead of IFA, prior to splenocyte fusion to the FL653 myeloma cell line after the method of Harlow and Lane (1998), Using Antibodies: A Laboratory Manual: Portable Protocol No. I, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. Briefly, splenocytes isolated from a
mouse 3 days after the final boost were washed twice and mixed in a 7:1 ratio with twice-washed log phase FL653 myeloma cells. The cell mixture was split four ways, pelleted, and incubated in 37° C. PEG for 1 min during which time cells were gently resuspended, followed by careful addition of 10 ml ice-cold DMEM. Cells were mixed, pelleted, and resuspended in AAT hybridoma growth selection media. Cell supernatants were screened for BCMA-specific reactivity by ELISA and flow cytometry. Clones that scored positive for BCMA and negative for Fc-specificity in an ELISA format, positive on BCMA-transfected cells, and negative on mock-transfected cells were expanded and subcloned. Four BCMA-specific clones were selected for further evaluation: C11D5.3 (IgG1), C12A3.2 (IgG1), C13F12.1 (IgG1) and A7D12.2 (IgG2b). Anti-BCMA mAbs were biotin-conjugated for use in ELISA and FACS experiments described below using a kit according to the manufacturer's recommendations (Molecular Probes, Eugene, Oreg.). - Total cellular RNA from murine hybridoma cells was prepared using a Qiagen RNeasy mini kit following the manufacturer's recommended protocol. cDNAs encoding the variable regions of the heavy and light chains were cloned by RT-PCR from total cellular RNA, using random hexamers for priming of first strand cDNA. For PCR amplification of the murine immunoglobulin variable domains with intact signal sequences, a cocktail of degenerate forward primers hybridizing to multiple murine immunoglobulin gene family signal sequences and a single back primer specific for the 5′ end of the murine constant domain were used. PCR was performed using
Clontech Advantage 2 Polymerase mix following the manufacturer's recommended protocol. The PCR products were gel-purified and subcloned into Invitrogen's pCR2.1TOPO vector using their TOPO cloning kit following the manufacturer's recommended protocol. Inserts from multiple independent subclones were sequenced to establish a consensus sequence. Deduced mature immunoglobulin N-termini were consistent with those determined by Edman degradation from the hybridoma. Assignment to specific subgroups was based upon BLAST analysis using consensus immunoglobulin variable domain sequences from the Kabat database (Johnson and Wu (2000), Nucleic Acids Res 28:214-218). CDRs were designated using the Kabat definitions (Johnson and Wu (2000), Nucleic Acids Res 28:214-218). - To validate specific binding to BCMA, anti-BCMA mAbs were screened on a stable BCMA-expressing CHO cell line. The stable BCMA-expressing CHO cell line was generated using a previously described method (Brezinsky et al. (2003), J Immunol Methods 277:141-155). Briefly, approximately 1.5 million dihydrofolate reductase (DHFR) deficient DG44 Chinese hamster ovary (CHO) cells were transfected with 4 μg PV90 plasmid DNA containing the human BCMA gene using Fugene 6 Transfection Reagent (Roche, Indianapolis, Ind.). Following transfection, the cells were cultured in 6-well culture dishes. Twenty-four hours post-transfection, the growth medium was changed to alpha minus MEM (Gibco, Rockville, Md.), 10% dialyzed serum (Hyclone, Logan, Utah), and 2 mM L-glutamine (Gibco, Rockville, Md.), and cells were pooled and split into three T-75 tissue culture flasks and allowed to grow to confluence. Seven days post-transfection, the cells were pooled again and split into five T225 tissue culture flasks and allowed to grow to confluence.
- Fourteen days post-transfection, the cells were incubated with the C4E2.2 Ab (6) and sorted for BCMA+ cells. These cells were grown in culture and sorted a second time, with positive cells sorted into 96-well plates. Clones were expanded and assessed for BCMA expression using clone C4E2.2.
- The highest expressing clone was used for assessing new anti-human BCMA mAbs, with untransfected CHO cells as a control. Briefly, BCMA-CHO cells were pretreated with FACS buffer plus 5% normal mouse serum to block non-specific binding sites. Seven anti-BCMA mAbs—C11D5.3, C12A3.2, C13F12.1 and A7D12.2 and the commercially available anti-BCMA mAbs, C4E2.2 (Legacy Biogen), VICKY-1 (Alexis) and 335004 (R&D Systems, Inc.)—and isotype control antibodies were incubated separately with cells for 30 minutes on ice at 1 μg/ml, and washed. Biotin-conjugated isotype control Abs were as follows: mouse IgG1, eBioscience cat. no. 13-4714-85; mouse IgG2a, eBioscience, cat. no. 13-4732-85; hamster IgG1, BD Pharmingen cat. no. 553970; rat IgG2a, eBioscience, cat. No. 13-4321-82. To visualize positive staining, Streptavidin-PE (Molecular Probes, Eugene, Oreg.) was added to cells for 30 minutes on ice, after which cells were washed, fixed in 0.8% paraformaldehyde, and run on a FACScalibur flow cytometer (BDbiosciences, San Jose, Calif.) and analyzed using Flowjo software (Treestar, Ashland, Oreg.). Results are shown in
FIG. 1 . - All seven antibodies showed specific recognition of the BCMA-expressing cells. C11D5.3 showed a slightly higher basal binding to the negative control cells than the control mAb; basal binding of the other six antibodies to the negative control cells was similar to that of the control Ab.
- The seven anti-BCMA mAbs tested in Example 3 were then assessed in a cross-blocking assay to determine the presence or absence of epitope overlap between each antibody. Corning 96-well flat-bottom plates were incubated overnight at 4° C. with 10 μg/ml of mouse anti-human Fc in a 50 mM pH 9.6 sodium bicarbonate solution, washed, incubated with 2 μg/ml human BCMA-Fc (SEQ ID NO:10) at 37° C. for 1 hr, washed again, and non-specific binding sites were blocked with blocking buffer (3% BSA in PBS) for 30 min at 37° C. Triplicate wells were then incubated with each unconjugated anti-BCMA mAb clone in blocking buffer at a concentration that was ten times the concentration of the single biotin-conjugated anti-BCMA mAb used in each individual experiment. A single biotin-conjugated anti-BCMA mAb clone in blocking buffer was added to all wells at a concentration pre-determined to give 80% of maximal signal (EC80) and incubated for 1 hr at 37° C., after which wells were washed and incubated with a streptavidin-HRP solution for 30 min, 37° C., washed, and incubated with substrate, TMB, to visualize positive reactivity. Enzymatic reactivity was stopped by adding 2N sulfuric acid, and the absorbance at 450 nm was measured using a plate reader.
- For each species of biotin-conjugated antibody, control readings in which the unconjugated and conjugated antibodies were the same (except for the presence/absence of conjugated biotin) were considered background levels, i.e., the absorbance from this control was subtracted from each experimental reading for that antibody. In some cases, this background subtraction resulted in slightly negative values. Although it is possible that the labeled antibody was blocked slightly more effectively by a different unconjugated antibody than by itself, these slightly negative values might also result from experimental variation. Results were then expressed as a percentage of the positive control value, i.e., the background-adjusted absorbance reading for the biotin-conjugated antibody in the absence of a competing unconjugated antibody.
- Antibodies were considered to bind the same epitope or very closely overlapping epitopes if they each reduced the other's binding (according to the fraction calculated as above) to below 20% of the positive control value. If they did not satisfy this condition, they were considered to have at least partially distinct epitopes. Table 3 shows which antibodies have at least partially distinct epitopes.
- Blood was obtained from consenting healthy volunteers and peripheral blood mononuclear cells (PBMCs) were enriched by centrifugation through Ficoll-Paque (GE Healthcare, UK) according to the manufacturer's recommendations. PBMCs were washed extensively in PBS prior to use. Cells were pretreated with FACS buffer containing 5% normal mouse serum to block non-specific binding sites. The following fluorphore-conjugated monoclonal antibodies directed against specific B cell and plasma cell markers were used: anti-CD19-PE-Cy5, anti-IgD-FITC, anti-CD27-APC, anti-CD38-PE-Cy7 (BD Biosciences, San Jose, Calif.). Streptavidin-PE (Molecular Probes, Eugene, Oreg.) was used to visualize biotin-conjugated anti-BCMA mAbs (10 μg/ml). Binding of an isotype control mAb as in Example 3 was also measured.
- None of the anti-BCMA mAbs stained naïve B cells from healthy volunteers (
FIG. 2E ), while all stained plasma cells, although with varying intensities (FIG. 2A ). Only clone A7D12.2 stained a proportion of all three memory B cell subsets (FIGS. 2B-D ). - Blood was obtained from consenting healthy volunteers and SLE patients and processed as in Example 5.
FIGS. 3A-D show a comparison between samples from a healthy volunteer and a representative SLE patient. Antibody A7D12.2 bound to plasma cells from both healthy volunteers and SLE patients (FIG. 3A ). In the SLE samples but not the healthy samples, the A7D12.2 antibody bound naïve B cells (FIG. 3E ). Binding of the A7D12.2 antibody to memory B cells (FIGS. 3B-3D ), particularly double negative memory B cells (FIG. 3D ), was increased in SLE samples. - CHO-DG44-I, a dhfr-deficient, insulin-independent Chinese hamster ovary cell line, was used to construct anti-BCMA wild type cell lines. The host cells were cultured in CHO-S-SFM II medium with nucleosides prior to transfection.
- Chimeric antibodies were produced by transfecting cells with expression plasmids encoding the mature heavy and light chain sequences listed in Table 4.
-
TABLE 4 Mature heavy and light chain sequences of chimeric anti-BCMA antibodies Chimeric Mature heavy antibody chain sequence Mature light chain sequence chA7D12.2 SEQ ID NO: 13 SEQ ID NO: 14 chC11D5.3 SEQ ID NO: 15 SEQ ID NO: 16 (for Example 8) SEQ ID NO: 17 (for Example 9) chC12A3.2 SEQ ID NO: 18 SEQ ID NO: 19 chC13F12.1 SEQ ID NO: 20 SEQ ID NO: 20 - Chimeric anti-BCMA expression plasmids were transfected into the CHO host cell line DG44-I using a cationic lipid (Fugene HD) method. Briefly, 1×106 DG44-I cells were seeded in each of two wells of a 6-well plate containing 3 mL of CHO-S-SFMII medium w/nucleosides per well. Four μg of plasmid DNA (2 μg heavy chain, 2 μg light chain) was diluted into 200 μL CHO-S-SFM II (Invitrogen) medium at room temperature. Sixteen μL of Fugene HD (Roche) reagent and allowed to complex with the DNA for approximately 15 minutes. 100 μL of the complexed DNA mixture was added to each well containing the cells. After three days, the transfected cells were combined and transferred to a T-75 flask containing 20 mL CHO-S-SFM II medium w/o nucleosides containing 400 μg/mL geneticin (Invitrogen). Cells were monitored for viability and scaled-up accordingly. As the cells were scaled-up they were adapted to production medium. Clonal cell lines were obtained by FACS sorting individual cells from the stable population.
- CHO-DG44-I cells stably transfected with chimeric heavy and light chains were fermented in CHOM39 media, harvested, and the cells were removed by centrifugation. The pH of the cleared media was adjusted prior to passing through a protein A Fast Flow column. Antibodies were eluted with 100 mM Na-citrate buffer, pH 3.0, neutralized to pH 7.0 using 10% (v/v) of 2M glycine, pH 8.9, and the recovered antibody solution was buffer-exchanged to PBS (pH 7.2) using a
Superdex 200 size exclusion chromatography under endotoxin-free conditions. The purified protein was kept at −80° C. - Cells and Cell Culture
- JJN-3 human plasmacytoma cells (DSMZ ACC 541) were cultured in culture medium consisting of 40% Dulbecco's MEM, 40% Iscove's MDM, 20% FBS, 100 units/mL penicillin and 100 μg/mL streptomycin. U266 human plasmacytoma cells (ATCC TIB 196) were cultured in culture medium consisting of RPMI 1640, 15% FBS, 20 mM HEPES, 100 units/mL penicillin and 100 μg/mL streptomycin. All cells were cultured at 37° C. in a 5% CO2 atmosphere. Peripheral blood mononuclear cells were isolated from a consented normal healthy donor by density centrifugation through Ficoll—Paque PLUS (GE Healthcare, Uppsala, Sweden).
- In Vitro Antibody-Dependent Cellular Cytotoxicity (ADCC) Assay
- Assay diluent was
RPMI 1640, 1% BSA, 20 mM HEPES, 100 units/mL penicillin and 100 μg/mL streptomycin. Human plasmacytoma cell lines JJN-3 and U266 were washed and resuspended in assay diluent to 0.4×106 cells per mL. 50 μL of each cell suspension was plated into a 96-well U bottom microtiter plate in triplicates. 50 μL of serially diluted chimeric anti-BCMA antibodies (chC12A3.2, chC13F12.1, chC11D5.3, and chA7D12.2, as described in Example 7) and control human IgG1 (HIgG1; Protos Immunoresearch, Burlingame, Calif.) were added to wells containing the cell lines and incubated for 30 minutes at 37° C. For an effector:target ratio of 25:1, 50 μL of PBMCs (500,000) were added and incubated for an additional four hours at 37° C. in a 5% CO2 atmosphere. Plates were centrifuged at 1200 rpm for 5 minutes, and 100 μL of supernatant was transferred to a 96-flat-bottom microwell plate. The level of cell lysis was determined by measuring the amount of lactate dehydrogenase (Cytotoxicity Detection Kit (LDH), #11 644 793 001 Roche) released from lysed cells. 100 μL of LDH kit reaction mixture was added to 100 μL of supernatant for up to 30 minutes as followed by manufacturer instructions. Absorbance was measured at 490 nm. Controls included target cells alone (spontaneous LDH release), target cells alone with 2% Triton X-100 in assay diluent (maximum LDH release), effector cells with and without target cells, and human IgG1 isotype control. - Results
- The human BCMA+ plasmacytoma cell line, U266, was utilized to test the ability of chimeric anti-BCMA antibodies to kill via ADCC. Human peripheral blood mononuclear cells (PBMCs) were used as effector cells. As shown in Table 5, chimeric mAbs C12A3.2 and C13F12.1 demonstrated marked ADCC activity relative to HIgG1 controls. Chimeric clones A7D12.2 and C11D5.3 also mediated ADCC, although to a lesser degree than C12A3.2 and C13F12.1.
-
TABLE 5 ADCC of U266 cells by anti-human BCMA mAbs % Maximal Killing mAb Clone % Killing at 1 nM (mAb concentration, nM) chC12A3.2 32 35 (4) chC13F12.1 20 20 (0.4) chA7D12.2 10 24 (100) chC11D5.3 18 ≥42 (≥100)1 1Maximum killing determination is incomplete - ADCC assays were also performed using a second BCMA+ plasmacytoma cell line, JJN-3, as the target cells. As shown in Table 6, chimeric C12A3.2, C13F12.1, and A7D12.2 also mediated ADCC of JJN-3 cells.
-
TABLE 6 ADCC of JJN-3 cells by anti-human BCMA mAbs % Maximal Killing mAb Clone % Killing at 1 nM (mAb concentration, nM) chC12A3.2 5 14 (100) chC13F12.1 3 ≥14(≥100)1 chA7D12.2 20 37 (100) 1Maximum killing determination is incomplete - Using enriched human NK cells as effector cells did not result in improved killing for chC12A3.2, chC13F12.1 or chA7D12.2. Rather, percent killing by NKs was diminished relative to PBMCs, indicating that NK cells are not the effector cells for chC12A3.2, chC13F12.1, or chA7D12.2 in the ADCC assays with U266 and JJN3 as target cells (data not shown). Generation of afucosyl variants of chC12A3.2, chC13F12.1, or chA7D12.2 did not improve activity of these mAbs (data not shown).
- Establishment of Humanized (HSC/NSG) Mice
- HSC/NSG mice provide a useful tool for testing in vivo biologic reagents specific for human protein targets since their immune system consists of functioning human cell types (Brehm et al. (2010), Clin Immunol [Epub ahead of print]). Humanized mice were generated as previously described (Pearson et al. (2008), Curr Protoc Immunol Chapter 15:Unit 15.21.PMID: 18491294). NOD/SCID/common gamma chain-deficient mice (NSG mice) were purchased from Jackson Laboratories (Bar Harbor, Me.). Mice were maintained and bred under specific-pathogen-free conditions in isolator cages. Breeding pairs were established and dams were monitored for pregnancy and delivery. Pups ranging in age from 2-6 days old were used to create humanized mice. Pups were lightly irradiated, receiving a dose of 1 Gy (100 rad) from a 137Cs irradiator. Pups were immediately injected intra-orbitally with approximately 50,000 CD34+CD3− human stem cells (HSC) derived from umbilical cord blood (All Cell LLC, purchased from StemCell Technologies Inc., Vancouver, BC, Canada), then returned to the dam. Pups were weaned at 21 days and caged with littermates according to gender. Starting at 3 months of age mice were bled via the facial vein into heparinized tubes and the whole blood was analyzed by flow cytometry for the presence of human cells. In brief, 100 μl whole blood was stained with a cocktail of mAbs, anti-human CD45-FITC, anti-human CD3-PE, anti-human CD19-PerCp, and anti-mouse CD45-APC (BD Biosciences, San Jose, Calif.). Mice were considered successfully humanized if they had at least 20% human CD45+ cells in whole blood of which 10% or more were human CD3+, the remainder being human B cells and other human hematopoietic cells. Mice were occasionally bled and analyzed to ensure that the humanization was stable, and were routinely analyzed 2 weeks prior to study enrollment.
- Flow Cytometry
- To identify plasma cells (PC) in human stem cell humanized NSG (HSC/NSG) mice, collagenase-digested spleens were subjected to flow cytometric analysis. Cells were incubated with a cocktail of mAbs directed to human cell lineage and to human B cell markers. The panel consisted of anti-human CD45, anti-human CD19, anti-human CD27, anti-human IgD, and anti-human CD38. Two markers used to exclude specific cell populations were anti-mouse CD45 and anti-human CD3. Cells identified as PC were human CD45+, human CD19+, human CD3-, human CD27+, human IgD- and human CD38bright. To identify BCMA+ cells the biotin-conjugated anti-human BCMA mAbs, C12A3.2 and A7D12.2, were used.
- In Vivo Cell Depletion Assay
- 5-6 month-old HSC/NSG mice received chimeric anti-BCMA mAb i.p. Human IgG1 with no known reactivity (Protos Immunoresearch) was used as a negative control. Blood was collected to prepare serum for analysis of human Ig isoform levels. At the study terminus the spleen was harvested, a single cell suspension was prepared, RBCs were lysed and cells were washed 3× with PBS/5% FCS and the cell number was determined. Cells were assessed by flow cytometry for T lineage cells, B lineage cells, and plasma cells.
- Assessment of Serum Human Ig Isotypes
- Serum levels of human IgM and IgG were determined using an ELISA format (Bethyl Laboratories Inc., Montgomery, Tex.) and a human immunoglobulin isotyping kit (Millipore, Billerica, Mass.), respectively, according to the manufacturer's protocol.
- Results
- Analysis of HSC/NSG mice aged 5-6 months revealed that among the diverse cell subsets assessed BCMA+ cells were only found in the B cell lineage. Within the B cell lineage, BCMA was found only on splenic PCs (human CD19+, human CD27+, IgD−, CD38 bright) (
FIG. 4 ), and not on naïve B cells (human CD19+, human CD27−, IgD+), unswitched memory B cells (human CD19+, human CD27+, human IgD+), or switched memory B cells (human CD19+, human CD27+, human IgD−) (data not shown). - To assess the ability of chimeric anti-human BCMA mAbs to deplete human PC, HSC/NSG mice received various amounts of chimeric anti-human BCMA clones chAC11D5.3, chC12A3.2, chC13F12.1, and chA7D12.2 (Example 7) twice weekly i.p. for 2 weeks, after which the presence of splenic PCs was determined. Splenic PCs from the HIgG1-treated control group were analyzed for expression of BCMA using the A7D12.2 and C12A3.2 clones and were confirmed to express cell surface BCMA (data not shown). PCs were identified using the flow cytometric parameters described above, and total cell numbers were determined from the flow cytometric dot plots (calculated as a percentage of the total human cell number). The numbers of naïve human B cells, unswitched memory human B cells, and switched memory human B cells were also determined.
- Treatment with chC12A3.2 (N=5) resulted in a statistically significant decline, 93% and 95%, in the number of splenic PCs at the 200 μg and 20 μg dose levels, respectively, when compared with control HIgG-treated mice (N=5) while the 2 μg dose also showed a marked decline (32%), although it was not statistically significant. Treatment with chC13F12.1 (N=5) resulted in a statistically significant decline, 88% and 51° A, in the number of splenic PCs at the 200 μg and 20 μg dose levels, respectively (
FIG. 5 ). No impact on the number of other B cell subsets or T cells was observed with chC12A3.2 and chC13F12.1 (data not shown). - Treatment with 200 μg of chC11D5.1 (N=2) or chA7D12.2 (N=1) resulted in an 89% and 97% reduction, respectively, in human PCs within the spleen when compared to HIgG-treated control mice (N=5) (
FIG. 6 ). Treatment with chA7D12.1 also resulted in a 2.6-fold decline in the number of splenic human switched memory B cells when compared to HIgG-treated mice (575 vs. 217 PCs/105 HuCD45+ cells, for HIgG and chA7D12.1, respectively). Although BCMA could not be detected on the surface of switched memory B cells in untreated humanized mice, it appears that while the level of BCMA was below the limit of detection by flow cytometry, it was sufficient to result in Ab-mediated killing. - To determine the impact of human PC depletion on serum human Ig levels in the HSC/NSG mice described above, human Ig subsets were analyzed. The chimeric anti-BCMA mAbs used in these studies were of the human IgG1 isoform, therefore human IgG1 levels could not be accurately evaluated. In some experimental cohorts, control-treated mice had very little and variable amounts of isotypes IgG1, IgG2, IgA and IgE (data not shown). As shown in Table 7, both chC12A3.2 and chC13F12.1 resulted in marked reductions in serum human IgM, especially at the higher dose levels. Chimeric C12A3.2 resulted in a 63%, 62% and 30% reduction in IgM for the 200, 20 and 2 μg dose levels, respectively. Chimeric C13F12.1 resulted in a 52%, 42% and 32% reduction in IgM for the 200, 20 and 2 μg dose levels, respectively.
-
TABLE 7 Serum human IgM levels (μg/mL) Treatment Treatment dose chC12A3.2 chC13F12.1 Human IgG1 (μg) Mean SD1 Mean SD Mean SD 200 70.22 37.4 91.13 26.5 190.6 67.3 20 73.02 32.2 110.34 47.3 ND 52 134.3 60.1 128.9 112.4 ND 1SD = standard deviation; 2p = 0.008; 3p = 0.02; 4p = 0.05; 5ND = not done - In a separate experiment, mice received chC12A3.2 (N=14) or HIgG1 control (N=9), and the control mice had readily detectable IgG2 and IgG3 isotypes as well as IgM. Chimeric C12A3.2-treated mice exhibited a significant depletion of splenic plasma cells, similar to that seen in
FIG. 5 (data not shown). As shown in Table 8, mice that received chC12A3.2 exhibited significantly reduced serum IgG2 and IgM levels when compared with HIgG-treated control mice. Chimeric C12A3.2-treated mice also had a marked reduction in serum IgG3, although the difference did not reach statistical significance when compared to control mice (Table 8). -
TABLE 8 Serum human immunoglobulin levels Serum Immunoglobulin (μg/mL) IgG2 IgG3 IgM Treatment Mean SE1 Mean SE Mean SE chC12A3.2 5.42 1.9 1.1 0.7 40.53 12.2 HIgG 19.2 7.6 6.9 4.1 114.3 19.1 1SE = standard error; 2p = 0.05; 3p = 0.003 - The embodiments within the specification provide an illustration of embodiments of the invention and should not be construed to limit the scope of the invention. The skilled artisan readily recognizes that many other embodiments are encompassed by the invention. All publications and patents cited in this disclosure are incorporated by reference in their entirety. To the extent the material incorporated by reference contradicts or is inconsistent with this specification, the specification will supersede any such material. The citation of any references herein is not an admission that such references are prior art to the present invention.
- Unless otherwise indicated, all numbers expressing quantities of ingredients, reaction conditions, and so forth used in the specification, including claims, are to be understood as being modified in all instances by the term “about.” Accordingly, unless otherwise indicated to the contrary, the numerical parameters are approximations and may vary depending upon the desired properties sought to be obtained by the present invention. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should be construed in light of the number of significant digits and ordinary rounding approaches.
- Unless otherwise indicated, the term “at least” preceding a series of elements is to be understood to refer to every element in the series. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/444,107 US20220213208A1 (en) | 2009-03-10 | 2021-07-30 | Anti-bcma antibodies |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15894209P | 2009-03-10 | 2009-03-10 | |
US16292409P | 2009-03-24 | 2009-03-24 | |
PCT/US2010/026825 WO2010104949A2 (en) | 2009-03-10 | 2010-03-10 | Anti-bcma antibodies |
US201113255610A | 2011-11-23 | 2011-11-23 | |
US14/596,769 US20150125460A1 (en) | 2009-03-10 | 2015-01-14 | Anti-bcma antibodies |
US15/065,641 US20170029518A1 (en) | 2009-03-10 | 2016-03-09 | Anti-bcma antibodies |
US16/026,242 US11111307B2 (en) | 2009-03-10 | 2018-07-03 | Anti-BCMA antibodies |
US17/444,107 US20220213208A1 (en) | 2009-03-10 | 2021-07-30 | Anti-bcma antibodies |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/026,242 Continuation US11111307B2 (en) | 2009-03-10 | 2018-07-03 | Anti-BCMA antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220213208A1 true US20220213208A1 (en) | 2022-07-07 |
Family
ID=42139515
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/255,610 Active 2031-01-16 US9034324B2 (en) | 2009-03-10 | 2010-03-10 | Anti-BCMA antibodies |
US14/596,769 Abandoned US20150125460A1 (en) | 2009-03-10 | 2015-01-14 | Anti-bcma antibodies |
US15/065,641 Abandoned US20170029518A1 (en) | 2009-03-10 | 2016-03-09 | Anti-bcma antibodies |
US16/026,242 Active US11111307B2 (en) | 2009-03-10 | 2018-07-03 | Anti-BCMA antibodies |
US17/444,107 Abandoned US20220213208A1 (en) | 2009-03-10 | 2021-07-30 | Anti-bcma antibodies |
Family Applications Before (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/255,610 Active 2031-01-16 US9034324B2 (en) | 2009-03-10 | 2010-03-10 | Anti-BCMA antibodies |
US14/596,769 Abandoned US20150125460A1 (en) | 2009-03-10 | 2015-01-14 | Anti-bcma antibodies |
US15/065,641 Abandoned US20170029518A1 (en) | 2009-03-10 | 2016-03-09 | Anti-bcma antibodies |
US16/026,242 Active US11111307B2 (en) | 2009-03-10 | 2018-07-03 | Anti-BCMA antibodies |
Country Status (21)
Country | Link |
---|---|
US (5) | US9034324B2 (en) |
EP (2) | EP2406284B9 (en) |
JP (2) | JP6061469B2 (en) |
KR (1) | KR101589785B1 (en) |
CN (2) | CN102421801B (en) |
AU (2) | AU2010224160A1 (en) |
CA (1) | CA2754938C (en) |
CY (1) | CY1118069T1 (en) |
DK (1) | DK2406284T5 (en) |
ES (1) | ES2593583T3 (en) |
HK (1) | HK1166333A1 (en) |
HR (1) | HRP20161194T1 (en) |
HU (1) | HUE029619T4 (en) |
IL (1) | IL214996A (en) |
LT (1) | LT2406284T (en) |
MX (2) | MX341884B (en) |
NZ (2) | NZ594985A (en) |
PL (1) | PL2406284T3 (en) |
PT (1) | PT2406284T (en) |
SI (1) | SI2406284T1 (en) |
WO (1) | WO2010104949A2 (en) |
Families Citing this family (213)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009132058A2 (en) * | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
US20130273055A1 (en) * | 2010-11-16 | 2013-10-17 | Eric Borges | Agents and methods for treating diseases that correlate with bcma expression |
US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
CN107936121B (en) | 2011-05-16 | 2022-01-14 | 埃泰美德(香港)有限公司 | Multispecific FAB fusion proteins and methods of use thereof |
DK3415531T3 (en) * | 2011-05-27 | 2023-09-18 | Glaxo Group Ltd | BCMA (CD269/TNFRSF17)-BINDING PROTEINS |
UA112434C2 (en) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | ANTIGENCY BINDING SPECIFICALLY Binds to ALL |
TWI679212B (en) | 2011-11-15 | 2019-12-11 | 美商安進股份有限公司 | Binding molecules for e3 of bcma and cd3 |
KR102229945B1 (en) * | 2012-04-11 | 2021-03-18 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | Chimeric antigen receptors targeting b-cell maturation antigen |
JP6694712B2 (en) * | 2012-11-01 | 2020-05-20 | マックス−デルブルック−セントラム フアー モレキュラーレ メデジン | Antibody against CD269 (BCMA) |
AU2013204922B2 (en) | 2012-12-20 | 2015-05-14 | Celgene Corporation | Chimeric antigen receptors |
EP2762497A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP2762496A1 (en) | 2013-02-05 | 2014-08-06 | EngMab AG | Method for the selection of antibodies against BCMA |
WO2014122144A1 (en) | 2013-02-05 | 2014-08-14 | Engmab Ag | BISPECIFIC ANTIBODIES AGAINST CD3ε AND BCMA |
WO2014152177A1 (en) | 2013-03-15 | 2014-09-25 | Anthrogenesis Corporation | Modified t lymphocytes |
AR095374A1 (en) | 2013-03-15 | 2015-10-14 | Amgen Res (Munich) Gmbh | UNION MOLECULES FOR BCMA AND CD3 |
ES2959480T3 (en) | 2014-02-07 | 2024-02-26 | Univ Mcmaster | T cell coupler - trifunctional antigen and methods and uses thereof |
JP6825910B2 (en) | 2014-03-26 | 2021-02-03 | ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト(ゲーエムベーハー)Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt (GmbH) | Flattop (Fltp) is a novel biomarker for β-cell maturation |
BR112016024481A2 (en) | 2014-04-25 | 2017-10-10 | Bluebird Bio Inc | chimeric mnd promoter antigen receptors |
AU2015254526B2 (en) * | 2014-04-30 | 2020-04-30 | Max-Delbruck-Centrum Fur Molekulare Medizin In Der Helmholtz-Gemeinschaft | Humanized antibodies against CD269 (BCMA) |
SI3151672T1 (en) | 2014-06-06 | 2021-03-31 | Bluebird Bio, Inc. | Improved t cell compositions |
EP3172237A2 (en) | 2014-07-21 | 2017-05-31 | Novartis AG | Treatment of cancer using humanized anti-bcma chimeric antigen receptor |
KR102524920B1 (en) | 2014-07-22 | 2023-04-25 | 아폴로믹스 인코포레이티드 | Anti-pd-1 antibodies |
SG10201900455YA (en) * | 2014-07-24 | 2019-02-27 | Bluebird Bio Inc | Bcma chimeric antigen receptors |
EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3177649B1 (en) | 2014-08-05 | 2024-02-28 | Apollomics Inc. | Anti-pd-l1 antibodies |
EP3023437A1 (en) | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
EP3029068A1 (en) | 2014-12-03 | 2016-06-08 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases |
PT3226897T (en) | 2014-12-05 | 2021-04-13 | Eureka Therapeutics Inc | Antibodies targeting b-cell maturation antigen and methods of use |
PL3227432T3 (en) | 2014-12-05 | 2024-03-11 | Memorial Sloan Kettering Cancer Center | Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof |
BR112017012502B1 (en) | 2014-12-12 | 2020-09-15 | Bluebird Bio, Inc. | POLYNUCLEOTIDE, CAR POLYPEPTIDE CODED BY THE SAID POLINUCLEOTIDE, VECTOR UNDERSTANDING THE SAID POLYNUCLEOTIDE, COMPOSITION UNDERSTANDING THE SAID VECTOR AND METHOD FOR GENERATING AN IMMUNE EFFECTIVE CELL UNDERSTANDING A CAR |
JP6913025B2 (en) * | 2015-04-13 | 2021-08-04 | ファイザー・インク | Therapeutic antibodies and their use |
IL297223A (en) | 2015-04-13 | 2022-12-01 | Pfizer | Chimeric antigen receptors targeting b-cell maturation antigen |
HUE051661T2 (en) * | 2015-05-18 | 2021-03-29 | Tcr2 Therapeutics Inc | Compositions and medical uses for tcr reprogramming using fusion proteins |
CN116808219A (en) * | 2015-07-24 | 2023-09-29 | 安可初克公司 | Gamma secretase modulators for the treatment of immune system dysfunction |
TWI829617B (en) | 2015-07-31 | 2024-01-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for flt3 and cd3 |
TWI796283B (en) | 2015-07-31 | 2023-03-21 | 德商安美基研究(慕尼黑)公司 | Antibody constructs for msln and cd3 |
PT3331910T (en) | 2015-08-03 | 2020-03-24 | Engmab Sarl | Monoclonal antibodies against bcma |
PL3337824T3 (en) | 2015-08-17 | 2021-04-19 | Janssen Pharmaceutica Nv | Anti-bcma antibodies, bispecific antigen binding molecules that bind bcma and cd3, and uses thereof |
WO2017058850A1 (en) | 2015-09-28 | 2017-04-06 | Regents Of The University Of Minnesota | Chimeric antigen receptor (car) t cells as therapeutic interventions for auto- and allo-immunity |
CN108473575B (en) * | 2015-11-13 | 2022-04-19 | 美国卫生和人力服务部 | anti-BCMA polypeptides and proteins |
US11479755B2 (en) | 2015-12-07 | 2022-10-25 | 2Seventy Bio, Inc. | T cell compositions |
DK3402515T3 (en) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | IMPROVED PROCEDURES FOR MONITORING THE IMMUNE STATUS OF AN INDIVIDUAL |
KR20180101623A (en) | 2016-02-03 | 2018-09-12 | 암젠 리서치 (뮌헨) 게엠베하 | PSMA and CD3 bispecific T cell engrafting antibody constructs |
EA039859B1 (en) | 2016-02-03 | 2022-03-21 | Эмджен Рисерч (Мюник) Гмбх | Bispecific antibody constructs binding egfrviii and cd3 |
EP3411402B1 (en) * | 2016-02-03 | 2021-12-22 | Amgen Research (Munich) GmbH | Bcma and cd3 bispecific t cell engaging antibody constructs |
MX2018009700A (en) * | 2016-02-17 | 2019-01-24 | Seattle Genetics Inc | Bcma antibodies and use of same to treat cancer and immunological disorders. |
US20200281973A1 (en) | 2016-03-04 | 2020-09-10 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
WO2017157305A1 (en) | 2016-03-15 | 2017-09-21 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
MA43603A1 (en) | 2016-04-01 | 2019-03-29 | Amgen Inc | Chimeric receptors and methods of use |
IL303785A (en) | 2016-04-01 | 2023-08-01 | Kite Pharma Inc | Chimeric antigen and t cell receptors and methods of use |
NZ746700A (en) | 2016-04-01 | 2023-04-28 | Kite Pharma Inc | Bcma binding molecules and methods of use thereof |
CN109641049B (en) | 2016-06-21 | 2023-07-07 | 特尼奥生物股份有限公司 | CD3 binding antibodies |
JP7109789B2 (en) | 2016-08-02 | 2022-08-01 | ティーシーアール2 セラピューティクス インク. | Compositions and methods for TCR reprogramming using fusion proteins |
CR20220578A (en) | 2016-09-14 | 2023-01-17 | Teneobio Inc | Cd3 binding antibodies |
ES2875959T3 (en) | 2016-10-07 | 2021-11-11 | Tcr2 Therapeutics Inc | Compositions and methods for T-cell receptor reprogramming using fusion proteins |
EP4295918A3 (en) | 2016-11-02 | 2024-03-20 | Bristol-Myers Squibb Company | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma |
WO2018098365A2 (en) | 2016-11-22 | 2018-05-31 | TCR2 Therapeutics Inc. | Compositions and methods for tcr reprogramming using fusion proteins |
BR112019012354A2 (en) | 2016-12-21 | 2019-11-26 | Teneobio Inc | anti-bcma heavy chain antibodies only |
WO2018144535A1 (en) | 2017-01-31 | 2018-08-09 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
AU2018222749B2 (en) | 2017-02-17 | 2024-04-18 | Fred Hutchinson Cancer Center | Combination therapies for treatment of BCMA-related cancers and autoimmune disorders |
AU2018228719B2 (en) | 2017-02-28 | 2023-03-30 | Affimed Gmbh | Tandem diabody for CD16A-directed NK-cell engagement |
EP3604340A4 (en) | 2017-03-24 | 2021-01-06 | Zenyaku Kogyo Co., Ltd | ANTI-IgM/B CELL SURFACE ANTIGEN BISPECIFIC ANTIBODY |
EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
US20200055948A1 (en) | 2017-04-28 | 2020-02-20 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
WO2018204427A1 (en) | 2017-05-01 | 2018-11-08 | Juno Therapeutics, Inc. | Combination of a cell therapy and an immunomodulatory compound |
US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
CA3063598A1 (en) | 2017-06-14 | 2018-12-20 | Dana-Farber Cancer Institute, Inc. | B-cell maturation antigen (bcma)-directed nanoparticles |
JP7303126B2 (en) | 2017-06-20 | 2023-07-04 | テネオバイオ, インコーポレイテッド | Anti-BCMA heavy chain only antibody |
US11427642B2 (en) | 2017-06-20 | 2022-08-30 | Teneoone, Inc. | Anti-BCMA heavy chain-only antibodies |
WO2019000223A1 (en) | 2017-06-27 | 2019-01-03 | Nanjing Legend Biotech Co., Ltd. | Chimeric antibody immune effctor cell engagers and methods of use thereof |
MA51447A (en) | 2017-08-01 | 2020-06-10 | Medimmune Llc | MONOCLONAL ANTIBODY-DRUG CONJUGATE AGAINST BCMA |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | Multispecific molecules that bind to bcma and uses thereof |
CN111133007A (en) | 2017-09-13 | 2020-05-08 | 特尼奥生物股份有限公司 | Heavy chain antibodies that bind extracellular enzymes |
JP7137619B2 (en) * | 2017-09-29 | 2022-09-14 | モガム・インスティテュート・フォー・バイオメディカル・リサーチ | Anti-BCMA antibody with high affinity for BCMA and pharmaceutical composition for cancer treatment containing same |
EP3694997A4 (en) | 2017-10-12 | 2021-06-30 | Mcmaster University | T cell-antigen coupler with y182t mutation and methods and uses thereof |
WO2019079569A1 (en) | 2017-10-18 | 2019-04-25 | Novartis Ag | Compositions and methods for selective protein degradation |
KR20200074997A (en) | 2017-11-01 | 2020-06-25 | 주노 쎄러퓨티크스 인코퍼레이티드 | Antibodies and chimeric antigen receptors specific for B-cell maturation antigens |
MX2020004572A (en) | 2017-11-01 | 2020-10-07 | Juno Therapeutics Inc | Chimeric antigen receptors specific for b-cell maturation antigen (bcma). |
BR112020008812A2 (en) | 2017-11-06 | 2020-10-27 | Juno Therapeutics Inc | combination of cell therapy and a gamma secretase inhibitor |
WO2019099639A1 (en) | 2017-11-15 | 2019-05-23 | Navartis Ag | Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies |
MX2020005651A (en) | 2017-11-30 | 2020-10-28 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof. |
JP2021505168A (en) | 2017-12-08 | 2021-02-18 | ジュノー セラピューティクス インコーポレイテッド | Methods for Producing Manipulated T Cell Compositions |
CN112041430A (en) | 2017-12-08 | 2020-12-04 | 朱诺治疗学股份有限公司 | Serum-free medium formulations for culturing cells and methods of use thereof |
AU2018392088A1 (en) | 2017-12-22 | 2020-08-13 | Teneobio, Inc. | Heavy chain antibodies binding to CD22 |
US20200368268A1 (en) | 2018-01-08 | 2020-11-26 | Novartis Ag | Immune-enhancing rnas for combination with chimeric antigen receptor therapy |
AU2019215031A1 (en) | 2018-01-31 | 2020-08-20 | Novartis Ag | Combination therapy using a chimeric antigen receptor |
US11807663B2 (en) | 2018-02-01 | 2023-11-07 | Innovent Biologics (Suzhou) Co., Ltd. | Fully humanized anti-B cell maturation antigen (BCMA) single-chain antibody and use thereof |
CN116082518A (en) | 2018-02-01 | 2023-05-09 | 南京驯鹿生物技术股份有限公司 | Chimeric Antigen Receptor (CAR) combined with BCMA and application thereof |
EP3674327A4 (en) | 2018-02-01 | 2021-05-05 | Nanjing Iaso Biotherapeutics Co., Ltd. | Chimeric antigen receptor (car) binding to bcma, and uses thereof |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
WO2019166650A1 (en) | 2018-03-02 | 2019-09-06 | Cdr-Life Ag | Trispecific antigen binding proteins |
CN113817066A (en) | 2018-04-13 | 2021-12-21 | 艾菲默德有限责任公司 | Natural killer cell-conjugated antibody fusion constructs |
WO2019226658A1 (en) | 2018-05-21 | 2019-11-28 | Compass Therapeutics Llc | Multispecific antigen-binding compositions and methods of use |
CA3098420A1 (en) | 2018-06-01 | 2019-12-05 | Novartis Ag | Binding molecules against bcma and uses thereof |
JP7438988B2 (en) | 2018-06-13 | 2024-02-27 | ノバルティス アーゲー | BCMA chimeric antigen receptor and its use |
WO2020004934A1 (en) * | 2018-06-26 | 2020-01-02 | 에이비엘바이오 주식회사 | Anti-bcma antibody and use thereof |
US11845797B2 (en) | 2018-07-03 | 2023-12-19 | Marengo Therapeutics, Inc. | Anti-TCR antibody molecules and uses thereof |
US11110123B2 (en) | 2018-07-17 | 2021-09-07 | Triumvira Immunologics Usa, Inc. | T cell-antigen coupler with various construct optimizations |
KR20210034032A (en) | 2018-07-19 | 2021-03-29 | 리제너론 파아마슈티컬스, 인크. | Bispecific anti-BCMA x anti-CD3 antibodies and uses thereof |
WO2020018922A1 (en) | 2018-07-20 | 2020-01-23 | Teneobio, Inc. | Heavy chain antibodies binding to cd19 |
KR20210057730A (en) | 2018-08-09 | 2021-05-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | Engineered cells and methods of producing compositions |
SG11202101130VA (en) | 2018-08-09 | 2021-03-30 | Juno Therapeutics Inc | Methods for assessing integrated nucleic acids |
JP2021534783A (en) | 2018-08-31 | 2021-12-16 | ノバルティス アーゲー | Method for producing chimeric antigen receptor-expressing cells |
WO2020047449A2 (en) | 2018-08-31 | 2020-03-05 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2020087065A1 (en) | 2018-10-26 | 2020-04-30 | Teneobio, Inc. | Heavy chain antibodies binding to cd38 |
SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
PE20211058A1 (en) | 2018-11-01 | 2021-06-07 | Juno Therapeutics Inc | SPECIFIC CHEMERIC ANTIGEN RECEPTORS FOR MEMBER D OF GROUP 5 OF CLASS C OF THE RECEPTOR COUPLED TO PROTEIN G (GPRC5D) |
EP3873943A2 (en) | 2018-11-01 | 2021-09-08 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
CN113573719A (en) | 2018-11-08 | 2021-10-29 | 朱诺治疗学股份有限公司 | Methods and combinations of therapy and T cell modulation |
SG11202009283QA (en) | 2019-01-16 | 2020-10-29 | Caribou Biosciences Inc | Humanized bcma antibody and bcma-car-t cells |
KR20210134339A (en) | 2019-02-25 | 2021-11-09 | 노파르티스 아게 | Mesoporous silica particle composition for viral delivery |
EP3942025A1 (en) | 2019-03-21 | 2022-01-26 | Novartis AG | Car-t cell therapies with enhanced efficacy |
BR112021019334A2 (en) | 2019-04-05 | 2021-12-07 | Teneobio Inc | Heavy chain antibodies that bind to psma |
US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
WO2020219742A1 (en) | 2019-04-24 | 2020-10-29 | Novartis Ag | Compositions and methods for selective protein degradation |
EP3967329A4 (en) | 2019-05-07 | 2023-06-14 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Engineered immune cell targeting bcma and use thereof |
WO2020224605A1 (en) | 2019-05-07 | 2020-11-12 | 亘喜生物科技(上海)有限公司 | Bcma-targeting engineered immune cell and use thereof |
AU2020291938A1 (en) | 2019-06-14 | 2022-01-20 | Teneobio, Inc. | Multispecific heavy chain antibodies binding to CD22 and CD3 |
CN112585168B (en) * | 2019-07-30 | 2022-04-15 | 上海翰森生物医药科技有限公司 | anti-BCMA antibodies, antigen binding fragments thereof, and medical uses thereof |
US20230374130A1 (en) | 2019-07-30 | 2023-11-23 | Qlsf Biotherapeutics, Inc. | Bispecific anti lrrc15 and cd3epsilon antibodies |
CN112409482B (en) * | 2019-08-20 | 2022-08-26 | 杭州尚健生物技术有限公司 | BCMA antibodies |
US20220331363A1 (en) * | 2019-09-20 | 2022-10-20 | Shanghai GenBase Biotechnology Co., Ltd. | Bcma-targeted antibody and chimeric antigen receptor |
WO2021108661A2 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Chimeric antigen receptors and uses thereof |
WO2021132746A1 (en) * | 2019-12-24 | 2021-07-01 | Abl Bio, Inc. | Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof |
JP2023507120A (en) | 2019-12-18 | 2023-02-21 | テネオフォー, インコーポレイテッド | A heavy chain antibody that binds to CD38 |
KR20220012314A (en) * | 2020-01-03 | 2022-02-03 | 살루브리스 (청두) 바이오테크 코., 리미티드 | Antibodies that bind BCMA and uses thereof |
CA3166420A1 (en) | 2020-01-14 | 2021-07-22 | Synthekine, Inc. | Il2 orthologs and methods of use |
CN111234020B (en) * | 2020-01-23 | 2020-10-23 | 和铂医药(苏州)有限公司 | BCMA binding protein and preparation method and application thereof |
WO2021154887A1 (en) | 2020-01-28 | 2021-08-05 | Juno Therapeutics, Inc. | Methods for t cell transduction |
KR20220152227A (en) | 2020-02-12 | 2022-11-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | BCA-directed chimeric antigen receptor T cell composition and methods and uses thereof |
CN113248611A (en) * | 2020-02-13 | 2021-08-13 | 湖南华康恒健生物技术有限公司 | anti-BCMA antibody, pharmaceutical composition and application thereof |
TW202146441A (en) | 2020-02-27 | 2021-12-16 | 瑞士商諾華公司 | Methods of making chimeric antigen receptor-expressing cells |
WO2021173995A2 (en) | 2020-02-27 | 2021-09-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
BR112022020333A2 (en) | 2020-04-10 | 2022-11-22 | Juno Therapeutics Inc | METHODS AND USES RELATED TO CELL THERAPY DESIGNED WITH A CHIMERIC ANTIGEN RECEPTOR THAT TARGETS B CELL MATURATION ANTIGEN |
CN116157125A (en) | 2020-04-28 | 2023-05-23 | 朱诺治疗学股份有限公司 | Combination of T cell therapy and immunomodulatory compounds for BCMA |
TW202330622A (en) | 2020-04-29 | 2023-08-01 | 美商泰尼歐生物公司 | Multispecific heavy chain antibodies with modified heavy chain constant regions |
EP4121172A1 (en) | 2020-04-29 | 2023-01-25 | Teneobio, Inc. | Multispecific heavy chain antibodies with modified heavy chain constant regions |
IL298046A (en) | 2020-05-11 | 2023-01-01 | Janssen Biotech Inc | Methods for treating multiple myeloma |
US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
JP2023529211A (en) | 2020-06-11 | 2023-07-07 | ノバルティス アーゲー | ZBTB32 inhibitors and uses thereof |
CR20220656A (en) | 2020-06-30 | 2023-03-01 | Teneobio Inc | Multi-specific antibodies binding to bcma |
WO2022035793A1 (en) | 2020-08-10 | 2022-02-17 | Precision Biosciences, Inc. | Antibodies and fragments specific for b-cell maturation antigen and uses thereof |
JP2023539453A (en) * | 2020-08-20 | 2023-09-14 | チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド | Single variable domain and antigen binding molecule that binds BCMA |
CA3188978A1 (en) | 2020-08-21 | 2022-02-24 | Sandeep Tharian Koshy | Compositions and methods for in vivo generation of car expressing cells |
WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
EP4229094A1 (en) | 2020-10-16 | 2023-08-23 | QLSF Biotherapeutics, Inc. | Multispecific binding compounds that bind to pd-l1 |
WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
US20230398148A1 (en) | 2020-11-04 | 2023-12-14 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
TW202233684A (en) | 2020-11-18 | 2022-09-01 | 美商泰尼歐生物公司 | Heavy chain antibodies binding to folate receptor alpha |
JP2024501971A (en) | 2020-12-31 | 2024-01-17 | サナ バイオテクノロジー,インコーポレイテッド | Methods and compositions for modulating CAR-T activity |
CN113024671B (en) * | 2020-12-31 | 2022-05-24 | 北京艺妙神州医药科技有限公司 | anti-BCMA antibody and application thereof |
CA3204161A1 (en) | 2021-01-11 | 2022-07-14 | Jagesh Vijaykumar SHAH | Use of cd8-targeted viral vectors |
CN117279953A (en) | 2021-02-16 | 2023-12-22 | 詹森药业有限公司 | Trispecific antibodies targeting BCMA, GPRC5D and CD3 |
CA3211138A1 (en) | 2021-02-25 | 2022-09-01 | Teneobio, Inc. | Anti-psma antibodies and car-t structures |
AU2022226565A1 (en) | 2021-02-26 | 2023-08-31 | Teneobio, Inc. | Anti-muc1-c antibodies and car-t structures |
KR20230165771A (en) | 2021-03-03 | 2023-12-05 | 주노 쎄러퓨티크스 인코퍼레이티드 | Combination of T cell therapy and DGK inhibitor |
CA3212343A1 (en) | 2021-03-17 | 2022-09-22 | Kazunori YOSHIKIYO | Gene encoding a chimeric receptor for an anti-acetylcholine receptor autoantibody |
CN117321417A (en) | 2021-03-22 | 2023-12-29 | 朱诺治疗学股份有限公司 | Method for determining the efficacy of therapeutic cell compositions |
WO2022204071A1 (en) | 2021-03-22 | 2022-09-29 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
TW202304994A (en) | 2021-04-02 | 2023-02-01 | 美商泰尼歐生物公司 | Agonistic anti-il-2r antibodies and methods of use |
WO2022216864A1 (en) | 2021-04-06 | 2022-10-13 | Teneobio, Inc. | Anti-cd19 antibodies and car-t structures |
GB2623199A (en) | 2021-04-08 | 2024-04-10 | Marengo Therapeutics Inc | Multifunctional molecules binding to TCR and uses thereof |
IL307598A (en) | 2021-04-16 | 2023-12-01 | Juno Therapeutics Inc | T cell therapy in patients who have had prior stem cell transplant |
WO2022221726A2 (en) | 2021-04-16 | 2022-10-20 | Juno Therapeutics, Inc. | Combination therapies with bcma-directed t cell therapy |
AU2022259688A1 (en) | 2021-04-16 | 2023-10-05 | Teneobio, Inc. | Anti-cd20 antibodies and car-t structures |
CN118056008A (en) | 2021-04-27 | 2024-05-17 | 诺华股份有限公司 | Virus vector production system |
CN117916256A (en) | 2021-05-06 | 2024-04-19 | 朱诺治疗学有限公司 | Methods for stimulating and transducing T cells |
TW202309522A (en) | 2021-05-11 | 2023-03-01 | 美商健生生物科技公司 | Methods and compositions for monitoring the treatment of relapsed and/or refractory multiple myeloma |
WO2022246293A1 (en) | 2021-05-19 | 2022-11-24 | Sana Biotechnology, Inc. | Hypoimmunogenic rhd negative primary t cells |
WO2022251367A1 (en) | 2021-05-27 | 2022-12-01 | Sana Biotechnology, Inc. | Hypoimmunogenic cells comprising engineered hla-e or hla-g |
WO2022271987A1 (en) | 2021-06-23 | 2022-12-29 | TeneoFour, Inc. | Anti-cd38 antibodies and epitopes of same |
US11453723B1 (en) | 2021-06-25 | 2022-09-27 | Mcmaster University | BCMA T cell-antigen couplers and uses thereof |
EP4362957A1 (en) | 2021-07-01 | 2024-05-08 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
KR20240046319A (en) | 2021-07-14 | 2024-04-08 | 사나 바이오테크놀로지, 인크. | Altered expression of Y chromosome-linked antigens in hypoimmunogenic cells |
AU2022310862A1 (en) | 2021-07-14 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Engineered t cell receptors fused to binding domains from antibodies |
WO2023004197A1 (en) | 2021-07-23 | 2023-01-26 | Teneoten, Inc. | Heavy chain antibodies binding to hepatitis b surface antigen |
WO2023015217A1 (en) | 2021-08-04 | 2023-02-09 | Sana Biotechnology, Inc. | Use of cd4-targeted viral vectors |
KR20240053673A (en) | 2021-08-11 | 2024-04-24 | 사나 바이오테크놀로지, 인크. | Inducible system for altering gene expression in hypoimmunogenic cells |
AU2022330406A1 (en) | 2021-08-20 | 2024-03-07 | Novartis Ag | Methods of making chimeric antigen receptor–expressing cells |
US20230192843A1 (en) | 2021-10-14 | 2023-06-22 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
WO2023069790A1 (en) | 2021-10-22 | 2023-04-27 | Sana Biotechnology, Inc. | Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods |
WO2023081735A1 (en) | 2021-11-03 | 2023-05-11 | Celgene Corporation | Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma |
WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
WO2023122337A1 (en) | 2021-12-23 | 2023-06-29 | Sana Biotechnology, Inc. | Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods |
CN114276452A (en) * | 2021-12-29 | 2022-04-05 | 源道隆(苏州)医学科技有限公司 | Nano antibody capable of being combined with BCMA (brain cell activating antigen) and application thereof |
TW202334400A (en) | 2021-12-30 | 2023-09-01 | 美商Tr1X股份有限公司 | Cd4+ t cells expressing il-10 and chimeric antigen receptors and uses thereof |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023152747A1 (en) | 2022-02-09 | 2023-08-17 | Hadasit Medical Research Services And Development Ltd. | Anti-bcma car to target immune-related disorders, compositions and method thereof |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023193015A1 (en) | 2022-04-01 | 2023-10-05 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
WO2023196996A2 (en) | 2022-04-08 | 2023-10-12 | 2Seventy Bio, Inc. | Multipartite receptor and signaling complexes |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2023213969A1 (en) | 2022-05-05 | 2023-11-09 | Juno Therapeutics Gmbh | Viral-binding protein and related reagents, articles, and methods of use |
WO2023220641A2 (en) | 2022-05-11 | 2023-11-16 | Juno Therapeutics, Inc. | Methods and uses related to t cell therapy and production of same |
WO2023220655A1 (en) | 2022-05-11 | 2023-11-16 | Celgene Corporation | Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy |
WO2023230548A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Method for predicting response to a t cell therapy |
WO2023230581A1 (en) | 2022-05-25 | 2023-11-30 | Celgene Corporation | Methods of manufacturing t cell therapies |
WO2024007020A1 (en) | 2022-06-30 | 2024-01-04 | Indapta Therapeutics, Inc. | Combination of engineered natural killer (nk) cells and antibody therapy and related methods |
WO2024026358A1 (en) | 2022-07-27 | 2024-02-01 | Teneobio, Inc. | Mesothelin binding proteins and uses thereof |
WO2024026377A1 (en) | 2022-07-27 | 2024-02-01 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
EP4311579A1 (en) * | 2022-07-29 | 2024-01-31 | Association Française contre les Myopathies | B cell-specific mab-sirna conjugates improve myasthenia |
WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
WO2024054944A1 (en) | 2022-09-08 | 2024-03-14 | Juno Therapeutics, Inc. | Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024077044A1 (en) | 2022-10-05 | 2024-04-11 | Amgen Inc. | Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
WO2024097905A1 (en) | 2022-11-02 | 2024-05-10 | Celgene Corporation | Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083785B2 (en) * | 1999-08-17 | 2006-08-01 | Biogen Idcc MA Inc. | Methods of treatment by administering an anti-BCMA antibody |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
CN101518648A (en) | 1999-01-07 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Soluble receptor BR43x2 and methods of using |
US7833529B1 (en) | 1999-01-07 | 2010-11-16 | Zymogenetics, Inc. | Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor |
US20060067933A1 (en) | 1999-01-07 | 2006-03-30 | Gross Jane A | Soluble receptor BR43x2 and methods of using |
WO2000068378A1 (en) | 1999-05-06 | 2000-11-16 | National Jewish Medical And Research Center | Tall-1 nucleic acid molecules, proteins, receptors and methods of use thereof |
CA2396793A1 (en) | 2000-02-16 | 2001-08-23 | Genentech, Inc. | Uses of agonists and antagonists to modulate activity of tnf-related molecules |
US20040002068A1 (en) | 2000-03-01 | 2004-01-01 | Corixa Corporation | Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
US7371388B1 (en) | 2000-05-04 | 2008-05-13 | Human Genome Sciences, Inc. | Treatment of Sjogren's syndrome by administration of TR18 polypeptides |
UA83458C2 (en) | 2000-09-18 | 2008-07-25 | Байоджен Айдек Ма Інк. | The isolated polypeptide baff-r (the receptor of the factor of activation of b-cells of the family tnf) |
JP2004533997A (en) | 2001-02-20 | 2004-11-11 | ザイモジェネティクス,インコーポレイティド | Antibodies that bind both BCMA and TACI |
CU23007A1 (en) * | 2001-04-06 | 2004-12-17 | Ct De Inmunologia Molecular Ct De Inmunologia Mole | IMMUNOTHERAPEUTIC COMBINATIONS FOR THE TREATMENT IMMUNOTHERAPEUTIC COMBINATIONS FOR THE TREATMENT OF TUMORS THAT OVER-EXPRESS GANGLIOSIDES TO OF TUMORS THAT OVER-EXPRESS GANGLOSIDES |
WO2003013582A1 (en) | 2001-08-06 | 2003-02-20 | Genset S.A. | Genoxit agonists and antagonists for use in the treatment of metabolic disorders |
AU2003221256A1 (en) * | 2002-02-21 | 2003-09-09 | Biogen Idec Ma Inc. | Use of bcma as an immunoregulatory agent |
EP1483295B1 (en) | 2002-03-01 | 2008-12-10 | Immunomedics, Inc. | Rs7 antibodies |
EP2322203A3 (en) | 2002-10-29 | 2011-07-27 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
US20050163775A1 (en) | 2003-06-05 | 2005-07-28 | Genentech, Inc. | Combination therapy for B cell disorders |
KR20060027801A (en) | 2003-06-05 | 2006-03-28 | 제넨테크, 인크. | Combination therapy for b cell disorders |
AU2006281978A1 (en) | 2005-08-12 | 2007-02-22 | Garvan Institute Of Medical Research | Phrophylactic and/or therapeutic method for treatment of autoimmune disease |
AU2006344395B2 (en) | 2005-10-13 | 2013-05-02 | Human Genome Sciences, Inc. | Methods and compositions for use in treatment of patients with autoantibody positive diseases |
DOP2006000277A (en) * | 2005-12-12 | 2007-08-31 | Bayer Pharmaceuticals Corp | ANTI MN ANTIBODIES AND METHODS FOR USE |
JP2007309746A (en) * | 2006-05-17 | 2007-11-29 | Osaka Univ | Method of analyzing binding site of cell membrane surface substance |
WO2008112017A2 (en) | 2006-10-10 | 2008-09-18 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Healtand Human Services | Avian influenza vaccine |
-
2010
- 2010-03-10 NZ NZ59498510A patent/NZ594985A/en unknown
- 2010-03-10 US US13/255,610 patent/US9034324B2/en active Active
- 2010-03-10 EP EP10708865.0A patent/EP2406284B9/en active Active
- 2010-03-10 AU AU2010224160A patent/AU2010224160A1/en not_active Abandoned
- 2010-03-10 PL PL10708865T patent/PL2406284T3/en unknown
- 2010-03-10 WO PCT/US2010/026825 patent/WO2010104949A2/en active Application Filing
- 2010-03-10 MX MX2013013076A patent/MX341884B/en unknown
- 2010-03-10 DK DK10708865.0T patent/DK2406284T5/en active
- 2010-03-10 LT LTEP10708865.0T patent/LT2406284T/en unknown
- 2010-03-10 HU HUE10708865A patent/HUE029619T4/en unknown
- 2010-03-10 PT PT107088650T patent/PT2406284T/en unknown
- 2010-03-10 KR KR1020117023294A patent/KR101589785B1/en active IP Right Grant
- 2010-03-10 CN CN201080020559.0A patent/CN102421801B/en active Active
- 2010-03-10 MX MX2011009430A patent/MX2011009430A/en active IP Right Grant
- 2010-03-10 CN CN201510142069.2A patent/CN104877026B/en active Active
- 2010-03-10 SI SI201031281A patent/SI2406284T1/en unknown
- 2010-03-10 CA CA2754938A patent/CA2754938C/en active Active
- 2010-03-10 NZ NZ61264710A patent/NZ612647A/en unknown
- 2010-03-10 JP JP2011554150A patent/JP6061469B2/en active Active
- 2010-03-10 EP EP16179507.5A patent/EP3141562A1/en not_active Withdrawn
- 2010-03-10 ES ES10708865.0T patent/ES2593583T3/en active Active
-
2011
- 2011-09-06 IL IL214996A patent/IL214996A/en active IP Right Grant
-
2012
- 2012-07-18 HK HK12107062.4A patent/HK1166333A1/en unknown
-
2014
- 2014-07-16 AU AU2014204447A patent/AU2014204447B2/en active Active
-
2015
- 2015-01-14 US US14/596,769 patent/US20150125460A1/en not_active Abandoned
- 2015-07-09 JP JP2015137493A patent/JP2015187164A/en active Pending
-
2016
- 2016-03-09 US US15/065,641 patent/US20170029518A1/en not_active Abandoned
- 2016-09-15 CY CY20161100917T patent/CY1118069T1/en unknown
- 2016-09-19 HR HRP20161194TT patent/HRP20161194T1/en unknown
-
2018
- 2018-07-03 US US16/026,242 patent/US11111307B2/en active Active
-
2021
- 2021-07-30 US US17/444,107 patent/US20220213208A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7083785B2 (en) * | 1999-08-17 | 2006-08-01 | Biogen Idcc MA Inc. | Methods of treatment by administering an anti-BCMA antibody |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20220213208A1 (en) | Anti-bcma antibodies | |
US20220064319A1 (en) | Human monoclonal antibody human cd134 (ox40) and methods of making and using same | |
TW202146056A (en) | Transglutaminase-mediated conjugation | |
US11795230B2 (en) | Anti-CD27 antibodies and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOGEN IDEC MA INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KALLED, SUSAN;HSU, YEN-MING;REEL/FRAME:057047/0038 Effective date: 20091028 Owner name: BIOGEN MA INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:BIOGEN IDEC MA INC.;REEL/FRAME:057047/0304 Effective date: 20150323 Owner name: BIOGEN IDEC MA INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KALLED, SUSAN;HSU, YEN-MING;REEL/FRAME:057047/0028 Effective date: 20091028 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |